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ABBREVIATIONS 
AAV adeno-associated virus 
Ab antibody 
AD Alzheimer’s disease 
ALS amyotrophic lateral sclerosis 
ANOVA analysis of variance 
APP amyloid precursor protein 
ATP adenosine triphosphate 
Aβ amyloid β 
BBB blood brain barrier 
bFGF basic fibroblast growth factor 
BM bone marrow 
BMSC bone marrow stem cells 
bp base pairs 
BSA bovine serum albumine 
CCR chemokine receptor 
CD cluster of differentiation 
CMV cytomegalovirus 
CNS central nervous system 
COX-2 cyclooxygenase-2 
cPPT the central polypurine tract 
CRD carbohydrate-recognition domain 
CX3CR-1 fractalkine receptor  
DAP12 DNAX activating protein of 12 kD 
DAPI 4',6-diamidino-2-phenylindole 
DNA deoxyribonucleic acid 
dpc days post-coitum 
EAE experimental autoimmune encephalomyelitis 
EB embryoid bodies 
EGF epidermal growth factor 
ERK extracellular signal-regulated protein kinase 
ES  Embryonic Stem  
FACS fluorescence activated cell sorting 
FBS fetal bovine serum 
FITC fluoro-isothiocyanate 
FIV feline immunodeficiency virus 
FSH follicle-stimulating hormone 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
GFP green fluorescence protein 
GM-CSF granulocyte-macrophage colony stimulating factor 
GRB2 growth-factor-receptor-bound protein 2 
h hours 
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hCG human Chorionic Gonadotropin 
HEK human embryonic kidney 
HIV human immunodeficiency virus 
HRP horseradish peroxidase 
Iba1 ionized calcium-binding adapter molecule 1 
ICAM intercellular adhesion molecules 
ICM inner cell mass 
INF Interferon 
Ig immunoglobulin 
IgSF immunoglobulin superfamily 
IL Interleukin 
ITAM immunoreceptor tyrosine based activation motif 
ITIM immunoreceptor tyrosine based inhibition motif 
iNOS inducible NOS 
ITSFn insulin transferring selenit fibronectin 
kg kilogram 
L liter 
LBP Lipopolysacharide binding protein 
LFA leukocyte function-associated molecule 
LH luteinizing hormone 
LIF leukemia inhibitory factor 
LPS lipopolysaccharides 
LTRs long terminal repeats 
M molar 
mAb monocolonal antibody 
MAG myelin-associated glycoprotein 
MAPK mitogen-activated protein kinase 
MCP monocyte chemoattractant protein 
MEF mouse embryonic fibroblast 
mES murine embryonic stem 
mg miligram 
MHC major histocompatibility complex 
min minutes 
ml milliliter 
mm millimeter 
mM millimolar 
MS Multiple Sclerosis 
NCAM Neural Cell Adhesion Molecule 
Neu5,(7)9Ac2 5,(7)9-N,O-diacetylneuraminic acid 
Neu5Ac N-acetylneuraminic acid 
Neu5Gc N-glycolylneuraminic acid 
ng nanogram 
NF-κB nuclear factor-kappa B 
nGS normal goat serum 
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nGOS neuronal NOS 
NK natural killer  
NO nitric oxide 
NOS nitric oxide synthase 
PAR-1 protease-activated receptor-1 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerytin 
PFA paraformaldehyde 
PGK phosphoglycerate kinase 
PI3-K Phosphoinositide 3-kinases 
PKB protein kinase B 
PLL poly-L-lysine 
PMS Pregnant Mare’s Serum 
PSA Poly sialic acid 
PTP protein tyrosine phosphatase 
RAGE receptors for advanced glycosylated endproducts 
RNA ribonucleic acid 
RRE the Rev response element 
RT room temperature 
RT-PCR reverse transcription PCR 
SEM standard error of the mean 
SHIP SH2-domain-containing inositol polyphhosphate 5-pohsphatase 
SHP SH2 domain-containing phosphatases 
Siglec Sia-recognizing Ig-superfamily lectins 
SIN self-inactivating 
Sn Sialoadhesin 
SSEA specific cell surface antigen 
SMP Schwann cell myelin protein 
syk spleen tyrosine kinase 
TAE Tris-acetate 
TBE Tris-borate 
TGF transforming growth factor 
TLR toll-like receptors 
TNF tumor necrosis factor 
TPA 12-O-tetradecanoylphorbol-13-acetate 
TU Transducing Units 
UDP uridine triphosphate 
VSV-G G protein of the vescular stomatitis virus 
WPRE wood chuck hepatitis virus post-transcriptional regulatory element 
µl microliter 
µm micrometer 
µg microgram 
Ψ retroviral packaging signal 
                                                                Introduction 
 8 
1 INTRODUCTION 
1.1 Siglecs 
1.1.1 Definition and nomenclature of Siglecs 
Animal glycan-recognizing proteins can be broadly classified into two groups: lectins, 
which typically contain an evolutionarily conserved carbohydrate-recognition domain 
(CRD), and sulfated glycosaminoglycan (SGAG)-binding proteins, which appear to have 
been evolved by convergent evolution. Proteins other than antibodies and T-cell receptors 
that mediate glycan recognition via immunoglobulin (Ig)-like domains are called “I-type 
lectins”. The major homologous subfamily of I-type lectins with sialic acid (Sia)-binding 
properties and characteristic amino-terminal structural features are called the “Siglecs” 
(Sia-recognizing Ig-superfamily lectins).  
Criteria for the inclusion of the immunoglobulin superfamily-related proteins as Siglecs 
were defined as:  (1) the ability to recognize sialylated glycans mediated by the N-terminal 
V-set domain via well-characterized molecular interactions, including a key arginine (Arg) 
residue that forms a salt bridge with the carboxylate group of sialic acid, and (2) significant 
sequence similarity within the N-terminal V-set and adjoining C2-set domains.  
There are currently 14 human and 9 mouse molecules that fulfill these criteria (Crocker, 
Paulson et al. 2007; Cao, Lakner et al. 2008) (Figure 1-1). Scientists in the field established 
the Siglec nomenclature of naming the members in order of discovery. Thus sialoadhesin 
(Sn) was given the designation Siglec-1, because it was the first member characterized as a 
Sia-binding lectin. Furthermore, categorizing CD22 as Siglec-2 and CD33 as Siglec-3, 
respectively, was useful as a “memory aid”. Mammalian myelin-associated glycoprotein 
(MAG) and avian Schwann cell myelin protein (SMP) were grouped together as Siglec-4a 
and -4b, respectively, because they are structurally and functionally related. Complexity in 
nomenclature arises from the fact that orthologs of some Siglecs in certain species have 
undergone mutations in an “essential” Arg residue required for optimal Sia binding and 
therefore no longer fulfill all the criteria to be called Siglecs. The first of these was found in 
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humans and initially called Siglec-L1 (Siglec-like molecule-1) (Angata, Varki et al. 2001). 
This molecule has a Sia-binding (“essential Arg”-containing) ortholog in the chimpanzee, 
designated as chimpanzee Siglec-12 (cSiglec-12). The international nomenclature group 
thus agreed to change the name of hSiglec-L1 to hSiglec-XII (the Roman numeral indicates 
that it is the Arg-mutated ortholog of cSiglec-12) (Angata 2004). Likewise, the Arg-mutated 
ortholog of hSiglec-5 in the chimpanzee is designated cSiglec-V, and the Arg-mutated 
Siglec-6 ortholog in baboon is bSiglec-VI. A primate molecule deleted in humans was 
discovered by sequencing the chimpanzee Siglec gene cluster and designated as Siglec-13 
(Angata, Margulies et al. 2004). In case of rodent CD33/Siglec-3-related Siglecs, 
alphabetical designations were applied, because it was difficult to assign the human 
orthologues of all rodents CD33/Siglec-3-related Siglecs. 
 
 
Figure 1-1.  Siglec-family proteins in humans and rodents. The brackets indicate low 
                                                                Introduction 
 10 
levels of expression. Siglec-12 in humans has lost the ability to bind sialic acids and is, 
hence, designated as Siglec-XII (not shown). Abbreviations: B, B cells; Ba, basophils; cDCs, 
conventional dendritic cells; Eo, eosinophils; GRB2, growth-factor-receptor-bound protein 
2; ITIM, immunoreceptor tyrosine-based inhibitory motif; Mac, macrophages; Mo, 
monocytes; MyP, myeloid progenitors; N, neutrophils; ND, not determined; NK, natural 
killer cells; OligoD, oligodendrocytes; pDCs, plasmacytoid dendritic cells; Schw, Schwann 
cells; Troph, trophoblasts. Figure modified from (Paul R. Crocker, 2007). 
 
1.1.2 Subfamilies of Siglecs 
On the basis of their sequence similarity and evolutionary conservation, Siglecs can be 
broadly divided into two groups: an evolutionary conserved subgroup, which includes 
Siglec-1, -2, -4 and -15, and a CD33/Siglec-3-related subgroup, which appears to be rapidly 
evolved (Table 1-1). The members of the first group are quite distantly related (~25–30% 
sequence identity), and have clear orthologues in all mammalian species examined. In 
comparison, the CD33-related Siglecs share ~50–99% identity but seem to be evolved 
rapidly by multiple processes, including gene duplication, exon shuffling, exon loss and 
gene conversion. This has resulted in important differences in the repertoires of 
CD33-related Siglecs among mammalian species. In humans, there are ten CD33-related 
Siglecs and one Siglec-like protein, including the recently defined Siglec-16 which was 
recognized as a pseudogene in the past (Cao, Lakner et al. 2008), whereas in mice there are 
five CD33-related Siglecs (Siglec-3 and E–H). 
Table 1-1. Evolutionary comparison of the two major subgroups of Siglecs. (Vaki et al. 
2006) 
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1.1.3 Expression pattern of human Siglecs 
Each human Siglec is expressed in a cell type-specific fashion, suggesting involvement in 
discrete functions. The selective expression of Sn/Siglec-1, CD22/Siglec-2, and 
MAG/Siglec-4 on tissue macrophages, mature B cells, and glial cells, respectively, appears 
to be conserved amongst all mammalian species studied so far.   
The CD33-related Siglecs appear to be variably distributed amongst cell types in the 
immune system, with significant overlaps (Figure 1-2). The striking exception are T cells in 
which very low expression of Siglecs is seen (Razi and Varki 1998), primarily Siglec-7 and 
-9 on a subset of CD8+ T cells in some humans (Nicoll, Ni et al. 1999; Zhang, Nicoll et al. 
2000; Ikehara, Ikehara et al. 2004). Also, Siglec-6 is expressed in placental trophoblast cells 
(Patel, Brinkman-Van der Linden et al. 1999).  
The cell type-specificity of human and mouse CD33-related Siglecs often do not follow 
their presumed orthologous relationships, for example, although human CD33/ Siglec-3 is 
highly expressed on mature monocytes, mouse CD33/Siglec-3 is expressed only on 
granulocytes (Brinkman-Van der Linden, Angata et al. 2003). Most CD33-related Siglecs 
are found on multiple leukocyte types to varying extents, for example, human 
CD33/Siglec-3, -5, -7, -9, and -10 are expressed on circulating monocytes. When monocytes 
are differentiated into macrophages or stimulated with lipopolysaccharide (LPS), they retain 
the expression of these Siglecs (Lock, Zhang et al. 2004). In comparison, monocyte-derived 
dendritic cells down-modulate Siglec-7 and -9 following maturation with LPS, and 
plasmacytoid dendritic cells in human blood express only Siglec-5. In a few instances, 
certain CD33-related Siglecs show expression predominantly restricted to one cell type. 
Although human Siglec-7 is found at low levels on granulocytes and monocytes, relatively 
high levels are found on a major subset of NK cells and a minor subset of CD8+ T cells 
(Nicoll, Ni et al. 1999). Siglec-8 could be detected only on eosinophils (Floyd, Ni et al. 
2000).  
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Figure 1-2. Expression pattern of human Siglecs within the hematopoietic system. 
Abbreviation: NK, natural killer. Figure modified from (Crocker and Varki 2001).  
 
1.1.4 Ligands of Siglecs 
1.1.4.1 Sialic acid 
Sialic acid (Sia) refers to a family of sugars that are typically found at the outermost end of 
glycan chains of all cell types (Schauer 2000; Angata and Varki 2002; Varki 2007). These 
acidic sugars with a nine-carbon backbone are mostly derived from N-acetylneuraminic acid 
(Neu5Ac). Although there are more than 50 forms of naturally occurring sialic acid, 
mammals mainly express Neu5Ac, N-glycolylneuraminic acid (Neu5Gc) and 5, (7)9-N, 
O-diacetylneuraminic acid (Neu5,(7)9Ac2) (Figure 1-3). Humans lack Neu5Gc owing to a 
mutation in the CMAH (cytidine monophosphate-N-acetylneuraminic acid hydroxylase) 
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gene, which encodes the enzyme required for the conversion of Neu5Ac to Neu5Gc. Sialic 
acids are usually located at the exposed, non-reducing ends of oligosaccharide chains, and 
are transferred using α2-3, α2-6 or α2-8 linkages to subterminal sugars by a family of about 
20 sialyltransferases. 
 
 
Figure 1-3. Sialic acids. a. Sketch of sialic acid with a nine-carbon backbone. In mammals 
sialic acid is commonly modified at the R and R′ positions with the substituents indicated. b. 
Two common sialoside sequences recognized as low-affinity ligands by many Siglecs are 
shown. Figure modified from (Crocker, Paulson et al. 2007). 
 
Sialic acids decorate all cell surfaces and most secreted proteins of vertebrates and ‘higher’ 
invertebrates, mediating or modulating a variety of normal and pathological processes. First, 
by virtue of their negative charge and hydrophilicity, sialic acids have many structural and 
modulatory roles. In a second category of functions, sialic acids serve as components of 
binding sites for various pathogens and toxins (Schauer 2000; Lehmann, Tiralongo et al. 
2006), such as human influenza A and C, or Helicobacter pylori. In most such interactions, a 
pathogen binding protein recognizes certain forms of sialic acids presented in specific 
linkages to a defined underlying sugar chain. Although this recognition is detrimental to the 
host expressing the cognate sialic acids, these molecules have nevertheless persisted on all 
cell types in all vertebrates for a long evolutionary time. Thus, a third set of function is the 
interaction with sialic acid binding proteins, which are intrinsic to the organisms. A final 
class of functions is “molecular mimicry”, in which successful microbial pathogens decorate 
themselves with sialic acids, which assist in evasion of host immunity (Vimr, Kalivoda et al. 
2004). 
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1.1.4.2 Structural feature of Siglecs for Sia-binding 
Most of the functional Siglecs studied to date have a conserved Arg residue in the V set 
domain that is required for optimal recognition of sialic acids. All Siglecs (other than 
Siglec-XII) contain an odd number (typically 3) of cysteine residues in the first and second 
Ig-like domains. Several other amino acid residues have also been defined to have direct 
contacts with sialylated ligands. For example, Trp2 and Trp106 in Sn/Siglec-1, and tyrosine 
26 (Tyr26) and tryptophan 132 (Trp132) in Siglec-7 (Yamaji, Teranishi et al. 2002) are 
reported to be involved in direct contacts with sialylated ligands. However, these features 
are not always common to the other siglecs. 
 
1.1.4.3 Recognition of Sias and their linkages by Siglecs 
In general, Siglecs show low affinity (a Kd of 0.1-3 mM) for the sialic acid Neu5Ac α2-3 
and α2-6 linkages to galactose ((Neu5Ac(α2-3)Gal and Neu5Ac(α2-6)Gal) that are 
commonly found as terminal sequences on glycans of glycoproteins and glycolipids of most 
mammalian cells (Bakker, Piperi et al. 2002; Blixt, Collins et al. 2003). And Siglecs have an 
overlapping specificity for such sialosides (sialic acid-containing glycans). However, when 
examined for their ability to recognize a diverse set of natural sialoside structures found in 
mammalian species, each Siglec shows a characteristic specificity profile for the types of 
sialic acid (Neu5Ac or Neu5Gc) and also for the types of linkage to subterminal sugars. For 
example, CD22 is unique in having a strong preference for Neu5Ac (α2-6) Gal and 
Neu5Gc(α2-6)Gal structures (Powell, Sgroi et al. 1993; Kelm, Schauer et al. 1994). Siglec-7 
and Siglec-11 prefer sialosides with the Neu5Ac (α2-8) Neu5Ac structure (Yamaji, 
Teranishi et al. 2002; Hayakawa, Angata et al. 2005). Of particular interest is the 
evolutionary loss of Neu5Gc in humans, as Neu5Gc is the preferred ligand for at least some 
Siglecs in the closely related great apes (Sonnenburg, Altheide et al. 2004).  
Furthermore, other aspects of the Sia molecules (Figure 1-4) could also affect the binding of 
Siglecs. The negatively charged carboxyl group of Sias is required for recognition by most 
Siglecs. A requirement of the glycerol-like side chain of Sias at C7-C9 for Siglec binding so 
far seems to be a general rule (Barnes, Skelton et al. 1999; Angata and Varki 2000; Angata 
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and Varki 2000; Brinkman-Van der Linden and Varki 2000) with exceptions such as 
Siglec-6 (Brinkman-Van der Linden and Varki 2000) and Siglec-11 (Angata, Kerr et al. 
2002).  
 
 
Figure 1-4. Structural features of sialic acids (Sias) affecting recognition by Siglecs. 
The most common Sia (Neu5Ac) is depicted with the nine carbon atoms numbered. The 
figure points to various structural features of Neu5Ac (and other Sias) that are known to 
affect recognition by Siglecs. The site of action of sialidases (neuraminidases) is also shown. 
(Varki, 2006) 
 
1.1.4.4 The interaction of Siglecs and sialosides 
It is of high significance that Siglecs can interact with ligands both in cis and in trans 
(Figure 1-5). Most Siglecs are masked at the cell surface owing to cis interactions with 
abundantly expressed sialic acids on the same cell (Freeman, Kelm et al. 1995; Hanasaki, 
Varki et al. 1995; Razi and Varki 1998). This interaction with cis ligands may dominate 
over interactions with trans ligands in modulating the biological activities of Siglecs 
(Crocker 2005). One exception to this rule is sialoadhesin/Siglec-1, which owes to its 
extended structure (16 V-set Ig domains), is thought to project its sialic-acid-binding site 
away from the plasma membrane and reduces its cis interactions (Munday, Floyd et al. 
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1999).  
Despite the likely importance of cis-ligand interactions in Siglec function, they do not 
necessarily prevent the binding of ligands in trans. Following exposure of cells to sialidase, 
which cleaves the cis-interacting Siglec ligands (Figure 1-4), or in some cases following 
cellular activation, Siglecs become unmasked, which allows them to make interactions with 
ligands in trans. Even when Siglecs are masked by cis interactions, trans interactions might 
occur during an encounter with another cell or a pathogen expressing higher affinity ligands 
that can out-compete the cis interactions.  
The most extensively characterized CD22/Siglec-2 on B cells serves as a good example to 
illustrate this. In B cells, owing to the interaction of CD22 in cis with sialic acids, CD22 is 
largely inaccessible to soluble, multivalent sialoside probes, in another word, CD22 is 
“masked”. However, the access to the CD22 receptor can be restored (unmasking) to bind 
ligands expressed on another cell (Collins, Blixt et al. 2004) when sialic acids are removed 
by sialidase treatment or in mice lacking the sialyltransferase ST6GAL1, which transfer 
sialic acids to galactose in α2-6 linkages (Collins, Blixt et al. 2002). Moreover, high-affinity 
synthetic sialoside probes can out-compete cis ligands for binding to CD22 on native B cells 
(Collins, Blixt et al. 2006). These results show that cis ligands down-regulate, but do not 
preclude, binding of ligands in trans, and that equilibrium-based binding of Siglecs to trans 
ligands can occur dynamically in the presence of cis ligands. 
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Figure 1-5. Cis and trans interactions of Siglecs. a. Most Siglecs are masked at the cell 
surface owing to cis interactions with abundantly expressed sialic acids. Following exposure 
of cells to sialidase, which cleaves the cis-interacting Siglec ligands, or in some cases 
following cellular activation, Siglecs become unmasked, which allows them to make 
interactions with ligands in trans. b. Even when Siglecs are masked by cis interactions, trans 
interactions might occur during an encounter with another cell or a pathogen expressing 
higher affinity ligands that can out-compete the cis interactions. (Crocker, 2007) 
 
1.1.4.5 Siglec recognition of other specific macromolecules 
Several studies have identified other specific ligands (or “counter receptors”) for Siglecs. 
These can be classified into ligands that interact with Siglecs via the sialylated glycans 
expressed on them and those interact independent of glycans, that is, via protein-protein 
interactions. 
For example, Sn/Siglec-1 was shown to be a counter receptor for the mannose receptor (a 
macrophage lectin) and the macrophage Gal-binding lectin (Martinez-Pomares, Crocker et 
al. 1999). The interaction was dependent on sulfated glycans on Sn, which served as a large 
carrier of glycan ligands for these lectins, rather than as Sia-binding Siglec (Fiete, Beranek 
et al. 1998). 
On the other hand, CD22/Siglec-2 was found to associate efficiently with IgM and CD45 at 
the surface of B cells independently of sialic acid recognition, despite the fact that these 
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proteins carry α2-6-linked sialic acids recognized by CD22 (Zhang and Varki 2004). 
Siglec-6 was also reported to interact with leptin independent of leptin glycosylation (Patel, 
Brinkman-Van der Linden et al. 1999). However, there has been no definitive report so far 
on glycan-dependent spedific-binding partner(s) for CD33-related Siglecs. 
 
1.1.5 Siglecs and intracellular signaling 
With the exception of a few ones, Siglecs generally have conserved immunoreceptor 
tyrosine-based inhibitory motif (ITIM) and/or ITIM-like motif in their cytosolic tails. The 
ITIMs are characterized by a typical 6-amino acid sequence described as (I/L/V) xYxx(L/V), 
where x denotes any amino acid (Vely and Vivier 1997). Once phosphorylated by a 
Src-family tyrosine kinase, this motif can interact with the Src homology domain 
2-containing phosphatases 1 (SHP-1, also known as protein tyrosine phosphatase (PTP)-1C 
or PTPN6) and SHP-2 (also known as PTP-1D or PTPN11), as well as with the 
SH2-domain-containing inositol polyphosphate 5-phosphatase (SHIP) (Figure 1-6). 
Transmembrane proteins with this motif in their cytoplasmic domains are generally 
considered to have inhibitory functions, dampening activating signals emitted by other 
cellular receptors with immunoreceptor tyrosine-based activatory motifs (ITAMs, with 
typical motif described as YxxLx6-8YxxL). 
In contrast, mouse CD33/Siglec-3 and Siglec-H, and human Siglec-14, Siglec-15, and 
Siglec-16 lack ITIM motifs. But they have a positively charged residue within the 
transmembrane region that is required to bind to the ITAM-containning adaptors, such as 
DAP12 and the Fc receptor γ-chain (Tomasello and Vivier 2005). These Siglecs thus might 
deliver activating signals through ITAM-dependent pathways (Figure 1-6). 
 
1.1.6 Function of Siglecs in the immune system 
In general, the most widely accepted explanation for the function of Siglecs is the detection 
of the “self sialome” and down regulation of the immune system via their ITIM motifs. 
Numerous studies point to important roles of CD33-related Siglecs in modulating leukocyte 
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behaviour, including inhibition of cellular proliferation (Vitale, Romagnani et al. 1999; 
Balaian, Zhong et al. 2003) induction of apoptosis (Nutku, Aizawa et al. 2003; von Gunten, 
Yousefi et al. 2005), inhibition of cellular activation (Paul, Taylor et al. 2000; Ulyanova, 
Shah et al. 2001; Avril, Floyd et al. 2004; Ikehara, Ikehara et al. 2004; Avril, Freeman et al. 
2005), induction of proinflammatory cytokine secretion (Lajaunias, Dayer et al. 2005) and, 
in the case of Siglec-H on plasmacytoid dendritic cells (pDCs), suppression of interferon-α 
(IFNα) production (Blasius, Cella et al. 2006) (Figure 1-6). CD33-related Siglecs can also 
function as endocytic receptors that could be important in the clearance of sialylated 
antigens and/or in promoting or inhibiting antigen presentation (Lock, Zhang et al. 2004; 
Walter, Raden et al. 2005; Nguyen, Ball et al. 2006; Zhang, Raper et al. 2006; Biedermann, 
Gil et al. 2007). Other functions that are well defined including the contribution for 
sialoadhesin in the pro-inflammatory functions of macrophages, CD22 as a regulator of 
B-cell signaling, homeostasis and survival by helping to set a threshold for antigen-induced 
activation of B cells (Doody, Justement et al. 1995). 
In addition, sialoadhesin and several CD33-related Siglecs can interact with sialic acids on 
Neisseria meningitidis, Campylobacter jejuni, group B Streptococcus and Trypanosoma 
cruzi (Jones, Virji et al. 2003; Monteiro, Lobato et al. 2005; Avril, Wagner et al. 2006; 
Carlin, Lewis et al. 2007). Siglec-dependent uptake of these pathogens could potentially 
benefit the host by promoting pathogen destruction and antigen presentation. 
 
Figure 1-6.   Signalling and fuctions mediated by CD22 and the CD33-related Siglecs. 
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↑, increased; ↓, decreased; IFNα, interferon-α. (Crocker, 2007) 
 
1.1.7 Siglec-11 
The recently discovered Siglec-11 belongs to the CD33-related subfamily of Siglecs 
(Angata, Kerr et al. 2002). The protein deduced from the full-length cDNA of Siglec-11 
consists of 5 extracellular Ig-like domains, a single pass transmembrane domain, and a 
cytosolic tail. Like most of the members of the CD33-related Siglecs, it has immunoreceptor 
tyrosine-based inhibitory motifs (ITIM) in the cytosolic domain, which have been shown to 
interact with protein-tyrosine phosphatases SHP-1 and/or SHP-2 (Src homology domain 
2-containing phosphatases 1 and/or 2), which are known to be involved in 
anti-inflammatory signalling of microglia (Horvat, Schwaiger et al. 2001) upon tyrosine 
phosphorylation (Angata, Kerr et al. 2002). However, Siglec-11 also has several novel 
features relative to the other CD33-related Siglecs. First, it binds specifically to alpha 
2-8-linked sialic acids, but the ligand molecule modified by 2-8-linked sialic acids and 
recognized by Siglec-11 has not been identified. Second, expression of Siglec-11 was not 
found on peripheral blood leukocytes, but on tissue macrophages in various tissues, such as 
liver Kupffer cells and brain microglia.  
Siglec-11 is identified as a human-specific gene expressed in microglia (Hayakawa, Angata 
et al. 2005). Analysis of genome data bases indicated that Siglec-11 has no mouse ortholog. 
Siglec-11 converted from a pseudogene in humans and chimpanzee, but not in bonobo, 
gorilla and orangutan. Histopathology demonstrated the expression of Siglec-11 on tissue 
macrophages in various human tissues, such as liver Kupffer cells, lamina propria 
macrophages in intestine, microglia in brain, and perifollicular cells in spleen. In 
inflammatory stomach, the infiltrating cells were also stained intensely. However, the 
expression of Siglec-11 was not found on peripheral blood leukocytes (Angata, Kerr et al. 
2002).  
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1.2 Microglia 
1.2.1 Microglia: parenchymal macrophage of the central nervous system 
(CNS) 
Microglia are one of the glial cells of the CNS. The term “glia” derived from the Greek 
word for “glue,” suggests that microglia share with astroglia and oligodendroglia the 
property of brain support and, more particularly, the support of neurons. However, such a 
supportive role in the healthy brain is better appreciated for astroglia, which make important 
contributions to neurotransmitter metabolism, and for oligodendroglia, which are the source 
of myelin, than for microglia. In the early 1980s, the macrophagic nature of microglia was 
formally established (Perry, Hume et al. 1985). Microglia are now known as the major 
immune cells of the CNS. They reside within the parenchyma of the nervous system sharing 
many, if not all the properties of macrophages in other tissues. And their role was defined as 
the first line of immune defense in CNS parenchyma (Kreutzberg 1996). 
Although microglia are “brain macrophages,” they are distinguished by their parenchymal 
location, morphology and phenotype from other types of brain macrophages such as 
meningeal and perivascular macrophages (Polfliet, Zwijnenburg et al. 2001; Nguyen, Julien 
et al. 2002; Polfliet, van de Veerdonk et al. 2002) and perivascular cells or pericytes 
(Thomas 1999; Williams, Alvarez et al. 2001), which are enclosed by a perivascular 
basement membrane within blood vessels and are not part of the CNS parenchyma. In 
particular, only microglia localize within the CNS parenchyma itself, in close contact with 
neurons, astrocytes and oligodendrocytes. Interestingly, a subpopulation of microglia, 
referred to as juxtavascular microglia, directly contacts the basal lamina of CNS blood 
vessels, at the blood–brain barrier (Lassmann, Zimprich et al. 1991; Gehrmann, Matsumoto 
et al. 1995). It is noteworthy that, despite their localization along blood vessels, 
juxtavascular microglia are phenotypically and morphologically distinct from perivascular 
macrophages (Kida, Steart et al. 1993). Under normal conditions, the adult mouse brain 
contains an average of 3.5x 106 microglial cells (Lawson, Perry et al. 1990). On a weight 
to-weight basis, microglia are thus as numerous as other tissue macrophages such as 
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Kupffer cells in the liver. 
 
1.2.2 Origin and turnover of microglia 
In rodents and humans, postnatal microglia are thought to arise from two different pools of 
myeloid cells that successively colonize the developing CNS. The first wave of microglial 
progenitors invades the embryonic and fetal CNS and derives essentially from 
extramedullary sources of hematopoiesis, including the yolk sac (Rezaie and Male 1999; 
Kaur, Hao et al. 2001). The second wave of microglial progenitors is formed by bone 
marrow (BM)–derived monocytic cells that colonize the CNS during the early postnatal 
period (P0–P15) in rodents, or before birth in humans (Cuadros and Navascues 1998). But 
the precise identity of these monocytic cells is yet not formally established. Passed the late 
phases of CNS development, the traffic of leukocytes from blood to CNS parenchyma is 
exquisitely controlled by the blood–brain barrier (BBB) (Bechmann, Galea et al. 2007). In 
the adult brain, resident microglia have a slow turnover at rest and are capable of 
proliferation and self-renew. Thus, the population of microglia in the adult under normal 
conditions is replenished intrinsically and does not require significant turnover from 
circulating blood progenitors (Lassmann and Hickey 1993; Kennedy and Abkowitz 1997).  
However, numerous reports showed that bone marrow stem cells (BMSCs) have the ability 
to populate the CNS and differentiate into functional parenchymal microglia as well as 
perivascular macrophage (Priller, Flugel et al. 2001; Priller, Persons et al. 2001; Vallieres 
and Sawchenko 2003; Simard and Rivest 2004; Massengale, Wagers et al. 2005). Even 
though BMSCs can enter the brain parenchyma throughout the CNS in normal mice, it 
seems that they are preferentially attracted to regions afflicted by neurodegeneration or 
neurological insults. In the case of cerebral ischemia, round donor-derived cells (most likely 
blood monocytes) enter the brain at the site of injury, and then migrate from the infiltration 
site and become ramified microglial cells. This is also true in models where the BBB is not 
compromised, such as in the case of facial nerve axotomy and hypoglossal nerve axotomy. 
It is reported that prion neuroinvasion is accompanied by a major recruitment of 
BM-derived microglia. Indeed, more than 50% of all brain microglia were replaced by 
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BM-derived cells before clinical disease onset and that in terminally sick mice, microglia 
density increased threefold to fourfold. These findings suggest that blood monocytes 
infiltrate the brain and later differentiate into ramified microglia, and that they are able to 
enter the CNS even if the BBB is intact and they can massively colonize the CNS in 
particular diseases. More importantly, these cells are recruited as a consequence of the 
disease and are not involved in the progression of the neuropathology (e.g. prion 
neuroinvasion). However, the exact mechanisms regulating microglia homeostasis remains a 
subject of debate.  
 
1.2.3 Role of microglia in the CNS 
The most characteristic feature of microglia is their rapid activation in response to 
pathological change in the CNS. They respond not only to changes in the brain parenchymal 
integrity but also to very small alterations in their microenvironment, such as imbalances in 
ion homeostasis that precede pathological changes (Gehrmann and Kreutzberg 1993). 
In the normal mature brain, microglia typically exist in a resting state characterized by 
ramified morphology, and monitor the brain environment by extending their processes over 
a multitude of nonoverlapping territories that cover the entire neural parenchyma. They are 
called quiescent microglia in this state. However, under a number of pathological conditions, 
quiescent ramified microglia will activate and engage a series of morphological alterations 
that lead to a hypertrophy of microglia cell body and a retraction of their ramifications. By 
the end of such a process, fully activated microglia, also called reactive microglia, harbor a 
similar morphology than any activated macrophage. Activated microglia were found to 
exert functions commonly assigned to all tissue-resident macrophages under inflammatory 
conditions. These include notably phagocytosis (Bauer, Sminia et al. 1994), antigen 
presentation (Perry 1998) and secretion of proinflammatory cytokines such as interleukin 6 
(IL-6), IL-1 or tumor necrosis factor α (TNF-α) (Banati, Gehrmann et al. 1993). 
The outcomes of the microglial activateion towards harmful or beneficial effect depend on 
the activating conditions. On the one hand, they have a critical role in host defense by 
removing invading microorganisms and neoplastic cells, or by secreting neurotrophic 
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factors. On the other hand, microglia may aggravate the effects of inflammation and cause 
neuronal degeneration. Over activated microglia could damage or induce apoptotic death of 
neurons, either directly through the release of toxic mediators such as cytokines and free 
radicals or indirectly by attracting activated T cells, monocytes, and neutrophils into the 
CNS. It is generally accepted that activated microglia function as a “double-edged sword,” 
with neuroprotective features predominating in the healthy nervous system and 
neurodestructive properties observed in various disease states such as in Alzheimer’s 
disease (AD), Parkinson’s disease, and Huntington’s disease etc (Stoll and Jander 1999; 
Hanisch and Kettenmann 2007). 
 
1.2.4 Molecules and signaling pathways involved in microglial activation 
LPS (abd-el-Basset and Fedoroff 1995; Kim and Joh 2006), an endotoxin from the 
gram-negative bacterial cell wall, is a potent immunostimulantor of microglia. Its 
recognition involves the binding of LPS to the serum protein LBP (LPS binding protein) 
and transfer of the complex by CD14 to the cognate receptor toll-like receptor 4 (TLR4) and 
the accessory protein MD-2. A variety of intracellular signaling molecules, such as protein 
tyrosine kinases, nitrogen-activated protein kinases, protein kinase C, small G proteins, and 
ceramide-activated protein kinase are involved in LPS-mediated activation. Through 
different signal transduction pathways, LPS activates transcription factors including NF-κB, 
NF-IL6, C/EBP and Fos/Jun families, and induces cytokine genes such as induced nitric 
oxide synthase (iNOS), TNF-α, IL-1β, IL-6, transforming growth factor β (TGF-β) (Sweet 
and Hume 1996). 
Interferon γ (IFN-γ), released from activated Th1 and NK cells, activates microglia to 
increase expression of MHC class I and class II molecules. With LPS, it synergistically 
induces IL-12 production from microglia. IFN-γ-mediated activation involves the 
JAK-STAT pathway. Briefly, IFN-γ stimulates the activation of receptor associated Jak1 and 
Jak2. This leads to the phosphorylation of a single receptor tyrosine residue, which is then 
recognized by the SH2 domain of Stat. It causes Stat phosphorylation followed by 
homodimerization, translocation into nucleus and induction of GAS (gamma-activation site) 
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driven target genes (Schindler 1999). 
Chemokines are small proteins (8 to 10 kDa) that induce chemotaxis, tissue extravasation 
and functional modulation of a wide variety of leukocytes during inflammation (Taub 1996). 
More than 40 distinct members are divided into 4 families typified by conservation of 
cysteine residues in the N-terminal sequence (Lusti-Narasimhan, Chollet et al. 1996). 
Chemokines mediate their effects via G protein-coupled receptors of the seven 
transmembrane domains. A number of chemokines are expressed in the CNS. They are 
related to a number of diseases of the CNS including stroke, multiple sclerosis (MS) and 
AD. Fractalkine/ neurotactin is a unique member of CX3C chemokine family which was 
discovered in 1997 (Bazan, Bacon et al. 1997). In the CNS, several populations of neurons 
express fractalkine mRNA constitutively that is not affected by stimuli such as cytokines, 
LPS and toxic stimuli (Amyloid β, glucose deprivation or glutamate). Membrane-bound 
fractalkine protein levels were decreased after excitotoxic glutamate stimuli (Chapman, 
Moores et al. 2000). Its receptor, CX3CR-1 is expressed at high levels in microglia 
(Nishiyori, Minami et al. 1998). Through its receptor, fractalkine induces intracellular Ca2+ 
mobilization, ERK activation and PI3-K-mediated PKB activation in microglia.  
CD40 is a 45-50 kDa transmembrane protein, which is a member of the TNFR (tumor 
necrosis factor receptor) superfamily (Vogel and Noelle 1998). It has been shown that CD40 
is constitutively expressed at low levels on microglia, and binding of microglial CD40 by 
CD40 ligand (CD40L) leads to marked TNF- secretion, which is neurotoxic at such levels 
(Aloisi, Penna et al. 1999). Activation of ERK1/2 is involved in CD40-CD40L mediated 
microglial activation (Tan, Town et al. 2000). Interestingly, stimulation with Amyloid β 
peptides (Aβ) and CD40L results in increased CD40 expression on microglia followed by 
TNF-α secretion. It has also been demonstrated that CD45 suppresses CD40L-induced 
microglial activation via negative regulation of the Src/ERK1/2 cascade. 
Aβ is the principal component of the extracellular deposits in AD (Selkoe 1989). Aβ 
promotes neurite outgrowth, generates reactive oxygen intermediates, induces cytotoxic 
cellular oxidative stress, and microglial activation (Koo, Park et al. 1993; Behl 1997; Sasaki, 
Yamaguchi et al. 1997). Although the mechanism by which Aβ causes enhanced expression 
of proinflammatory cytokines from microglia is not fully understood, there is evidence that 
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Aβ may interact with cell-surface receptors, including receptors for advanced glycosylated 
endproducts and scavenger receptors (El Khoury, Hickman et al. 1996; Yan, Chen et al. 
1996). Additionally, calcium, protein kinase C, and protein tyrosine kinase-dependent 
second messenger pathways have been postulated in Aβ receptor-mediated signal 
transduction (Lorton 1997; Combs, Johnson et al. 1999). Aβ activates microglia through 
these signal transduction pathways to induce the secretion of neurotoxic substances 
including TNF-α and IL-1, enhancing likely neuroinflammation in AD brain (Mrak and 
Griffin 2001; Smits, de Vos et al. 2001).  
Gangliosides, the sialic acid-containing glycosphingolipids, have also been reported as 
microglial activators (Pyo, Joe et al. 1999). Gangliosides exist in mammalian cell 
membranes and are particularly rich in the neuronal cell membrane. Gangliosides induce 
production of nitric oxide (NO), TNF- and cyclooxygenase-2 (COX-2) in microglia by 
activation of MAPKs (mitogen-activated protein kinases). Studies show that signals are 
released from neurons when they start to die. Upon potassium deprivation, cerebellar 
granule cells release signal molecules that can activate microglia (Tanaka, Suzuki et al. 
1998). Supernatant from serum-deprived immortalized motor neurons can also activate 
microglia and induce release of NO that causes neuronal death. These signals from dying 
neurons may be potent candidates for microglial activation.  
Thrombin-mediated microglial activation has been reported (Moller, Hanisch et al. 2000). 
Thrombin is generated from the precursor prothrombin that is endogenously expressed in 
human, mouse, and rat brain, including dopaminergic neurons in the CNS (Dihanich, Kaser 
et al. 1991; Soifer, Peters et al. 1994; Weinstein, Gold et al. 1995). Thrombin-induced 
microglial activation involves protease-activated receptor-1 (PAR-1) (Suo, Wu et al. 2002). 
Studies demonstrated that direct injection of thrombin into various brain regions including 
hippocampus and substantia nigra results in induction of iNOS, COX-2 and NADPH 
oxidase-mediated superoxide generation from microglial and subsequent neuronal 
degeneration (Choi, Lee et al. 2003; Choi, Lee et al. 2005).  
 
 
                                                                Introduction 
 27 
1.3 Lentiviral vector system 
1.3.1 General concept of viral vectors 
Viruses are dependent on their host cell to carry their genome. They are intracellular 
parasites that have developed efficient strategies to invade host cells and, in some cases, 
transport their genetic information into the nucleus either to become part of the host’s 
genome or to constitute an autonomous genetic unit. Viral vectors are the widely used 
vehicles developed from some natural virus to deliver genes to target cells. Viral vector 
comprises the viral sequences that are required for the assembly of viral particles, the 
packaging elements that can package the viral genome into the particles, the cassettes that 
are required to deliver the gene of interest (also termed transgene) to the target cells, and the 
transgene. Dispensable genes from the viral genome are deleted to reduce patho- and 
immunogenicity.  
Viral vectors can be divided into two general categories (Pfeifer and Verma 2001): (a) 
integrating vectors, capable of providing life-long expression of the transgene, and (b) 
non-integrating vectors. Examples for integrating vectors are retroviral and 
adeno-associated virus (AAV)–derived vectors. The major non-integrating vector currently 
employed is based on adenoviruses, and the viral DNA is maintained as an episome in the 
infected cell. Each of these vectors has specific advantages and major limitations. It is 
accepted that an ideal vector should fulfill the following requirements (Somia and Verma 
2000): 
1. Efficient and easy production. High-titer preparations of vector particles should be 
reproducibly available. The efficient transduction of cells is only possible if a sufficient 
number of infectious particles reach the target cells. For the widespread use of viral vectors, 
facile production procedures have to be developed. 
2. Safety aspects. The vector should neither be toxic to the target cells nor induce unwanted 
effects, including immunological reactions against the viral vector or its cargo. The latter 
carries not only the threat of eliminating the vector and/or the infected cells but also may 
lead to life-threatening complications, such as septic shock. 
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3. Sustained and regulated transgene expression. The gene delivered by the viral vector has 
to be expressed in a proper way. Permanent or even life-long expression of the therapeutic 
gene is desired only in a minority of diseases (e.g., treatment of hemophilia). Controlled 
expression of the transgene in a reversible manner would be highly desirable in many cases. 
4. Targeting of the viral vectors. Preferential or exclusive transduction of specific cell types 
is very desirable. 
5. Infection of dividing and nondividing cells. Because the majority of the cells in an adult 
human being are in a postmitotic, nondividing state, viral vectors should be able to 
efficiently transduce these cells. 
6. Site-specific integration. Integration into the host genome at specific site(s) is especially 
helpful in gene targeting. 
 
1.3.2 Constitution of lentiviral vectors 
Lentiviruses belong to complex retroviruses, a group of RNA virus. The term “lenti” derives 
from “lente” in Latin, which means slow. Two outstanding features of lentiviruses make 
them a very attractive tool for gene delivery. The first is their ability to infect nondividing, 
terminally differentiated mammalian cells. HIV (human immunodeficiency virus)-derived 
lentiviral vectors transduce a broad spectrum of nondividing cells in vivo and in vitro, such 
as neurons (Naldini, Blomer et al. 1996), retinal cells (Miyoshi, Blomer et al. 1998; 
Takahashi, Miyoshi et al. 1999), muscle cells (Kafri, Blomer et al. 1997), and hepatocytes 
(Pfeifer, Kessler et al. 2001). And the second is the ability to efficiently deliver large (»8 kb) 
and complex transgenes to the target cells and tissues (Trono 2000). 
Lentiviral vectors have been derived from HIV-1 (Naldini, Blomer et al. 1996; Poeschla, 
Corbeau et al. 1996; Reiser, Harmison et al. 1996), HIV-2 (Poeschla, Gilbert et al. 1998), 
feline immunodeficiency virus (FIV) (Poeschla, Wong-Staal et al. 1998), equine infectious 
anemia virus (Olsen 1998), simian immunodeficiency virus (SIV) (Mangeot, Negre et al. 
2000), and maedi/visna virus (Berkowitz, Ilves et al. 2001). But most of the lentiviral 
vectors presently in use for gene therapy approaches are HIV-derived vectors.  
To increase safety in practice, the lentiviral vector system is divided into vector constructs 
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and helpful packaging vectors (Figure 1-7). Cis- and trans-acting factors of lentiviruses are 
separated into different plasmids while preserving their functions. The vector constructs 
contain the viral cis elements, packaging sequences (ψ), the Rev response element (RRE), 
the central polypurine tract (cPPT), and the transgene and its expression regulatory elements, 
while the lentiviral packaging systems provide in trans the viral proteins that are required 
for the assembly of viral particles in the packaging cells.  
The long terminal repeats (LTRs) are viral sequences containing many cis-acting control 
elements for reverse transcription of the vector RNA and integration of the proviral DNA. 
The LTRs are divided into the U3, R, and U5 regions. In lentivirus, the U3 region in the 5’ 
LTR is replaced with the immediate early region of the human cytomegalovirus (CMV) 
enhancer-promoter. The CMV/LTR hybrid has a high transcriptional activity, especially 
when introduced in the appropriate cell lines (Finer, Dull et al. 1994), e.g., human 
embryonic kidney (HEK), 293 cells. This cell line expresses the adenoviral E1 gene 
products (Graham, Smiley et al. 1977) that superactivate the CMV promoter (Gorman, Gies 
et al. 1989). The 3’ LTR contains the cis-acting control elements involved in 
posttranscriptional processing of the 3’ end of the viral RNA (e.g., polyadenylation). The 
promoter/enhancer sequences of the U3 region of the 3’LTR is deleted or mutated so that 
the viral vectors are self-inactivating (SIN). This could avoid the problem of insertional 
activation of cellular oncogenes through the promoter and enhancer elements of the proviral 
LTR.  
The packaging sequences (ψ) are required for encapsidation of the vector RNA. The Rev 
response elements (RRE) could be recognized by the Rev protein of HIV which promotes 
the efficient transport of unspliced RNAs containing RRE from the nucleus to the cytoplasm. 
The central polypurine tract (cPPT) is to enhance nuclear translocation of the vector in the 
target cell.  
The transgene in lentiviral vectors is normally regulated by internal promoters such as CMV 
promoter or other tissue specific promoter to restrict the expression to a specific cell type or 
tissue. In addition, this approach allows the incorporation of regulatable transcriptional 
elements that may be switched on and off via exogenous stimuli, for example the 
tetracycline-regulated system, in which the transgene expression is induced in a 
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tet-dependent manner. Another example is the inclusion of Flap elements, which could work 
together with Cre to regulate the expression of transgene.  
An important improvement of the lentiviral vectors compared to other retroviral vectors is 
the inclusion of cis-acting transcriptional regulatory elements, such as the WPRE (wood 
chuck hepatitis virus post-transcriptional regulatory element), which enhances transgene 
expression in the target cells. The WPRE has to be present within the transgene transcript in 
sense orientation and is placed 3’ of the transgene cDNA upstream of the 3’ LTR. 
To package the replication-defective vector into virions, the necessary viral proteins are 
provided in trans in the packaging cell. Studies on HIV-1 demonstrated that structural 
components of lentiviruses can be provided in trans by packaging plasmids, and viral 
particles can be assembled by expressing viral proteins in packaging cells. The third 
generation of lentiviral packaging constructs includes three plasmids. One plasmid carries 
gag, pol (the two necessary viral gene), and the HIV RRE. A separate expression plasmid 
encodes Rev, which facilitates the expression of gag and pol. The third plasmid incorporates 
the G protein of the vescular stomatitis virus (VSV-G). The major advantages of 
incorporation of the VSV-G protein are (a) the extremely broad host range of VSV, which 
enters the host cell by membrane fusion via the interaction with phospholipid components of 
the cell membrane (Mastromarino, Conti et al. 1987) and (b) the ability to concentrate 
VSV-G pseudotyped particles more than 1000-fold (titers >109 IU/ml) by 
ultracentrifugation (Burns, Friedmann et al. 1993), which has important practical 
implications. Splitting the packaging genome into multiple units not only increases the 
safety of lentiviral vectors but also facilitates pseudotyping of lentiviral vectors with the 
envelope of different viruses. 
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Figure 1-7. Sketch of lentivial vectors system. A. key components of lentiviral vectors. B. 
sketch of packaging vectors. (Pfeifer and Verma 2001) 
 
 
1.4 Transgenic mice 
1.4.1 Transgenic mouse as an invaluable model 
A transgenic animal is one that carries a foreign gene that has been deliberately inserted into 
its genome. The ability to introduce and express exogenous genes of interest in animals has 
become an indispensable tool to modern biologists (Jaenisch 1988). Using transgenic 
techniques, a characterized genetic sequence may be evaluated within the specific genomic 
background of the whole animal. Currently the most common uses of transgenic animals are 
(1) for studies of tissue-specific and developmental-stage-specific gene regulation and (2) 
for experiments of the phenotypic effects of transgene expression. Among the experimental 
animals, mouse is chosen as a widely used model for good reasons (Gondo 2008). Not only 
because it is closely related to humans but also because it has more than 100 years of history 
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in genetic analysis. Over this period many mutants were identified, a number of inbred lines 
were established and gene mapping had been conducted more extensively than in any other 
mammalian species. Mouse exhibits a short life span with the large litter size that is suitable 
for genetic studies. In addition, mouse is currently the only species for which embryos can 
be manipulated using available ES-cell (embryonic stem cell) technologies. Furthermore, 
technologies for freezing embryos and gametes are well established in mouse, allowing in 
vitro fertilization to be combined with embryo transfer methods. Thus, valuable mouse lines 
can be easily and stably maintained in liquid nitrogen for many years while requiring 
minimal space and manpower. 
Plenty of technologies have been developed to control the expression of interested genes 
and facilitated the generation of transgenic mouse, among them are gene targeting (Smithies, 
Gregg et al. 1985; Wong and Capecchi 1986; Capecchi 2005) including knockout and 
knockin, specific expression of trangene using tissue specific promoters, introduction of 
dominant negative mutations to eliminate the activities of the wild-type gene products, 
insertion of a transgene as a mutagen, and disruption of the gene functions by RNA 
interference. Furthermore, the employment of inducible regulation approaches (Lewandoski 
2001), such as the Cre/loxP (Akagi, Sandig et al. 1997), the Flp/Frt (Theodosiou and Xu 
1998) and the tetracycline system (Berens and Hillen 2003), have greatly expanded the 
spectrum of transgenic mice. In cases where mutations could provoke lethality during 
development or invalidation of wildly expressed genes might lead to a complex phenotype 
affecting multiple tissues, it was limited to create mouse carrying such kinds of mutations. 
However, when applying inducible systems, the expression of such mutations could be 
rendered conditional, thus make it possible to generate mouse expressing the transgenes or 
mutations only in a specific time period or in one of the interested tissue. 
Two methods of producing transgenic mouse are widely used, one is injecting the desired 
gene into the pronuclear of a fertilized mouse egg (Rulicke and Hubscher 2000), and the 
other is using transformed ES cells with the desired DNA (Robertson 1991). 
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1.4.2 Generation of transgenic mouse through pronuclear injection 
The pronuclear microinjection method (Rulicke and Hubscher 2000) is the most extensively 
and successfully used method of gene transfer in mouse. It means microinjection of a 
purified double-stranded DNA sequence directly into the pronuclei of fertilized zygotes to 
produce a transgenic animal. If this transgene is integrated into one of the embryonic 
chromosomes, the animal will be born with a copy of this new information in every cell. 
The animal that develops after receiving the transgene DNA is referred to as the founder (F0) 
of a new transgenic lineage. If the germ cells of the founder transmit the transgene stably, 
then all descendants of this animal are members of a unique transgenic lineage. A 
homozygous genotype may be produced by the mating of a pair of hemizygous F1 siblings 
(Fig 1-8).  
Despite the relatively simpleness, this method has some shortcomings. Firstly, integration of 
foreign DNA into the embryonic genome generally is a random event with respect to the 
chromosomal locus. Therefore the probability of identical integration events in two embryos 
receiving the same transgene is overwhelmingly unlikely. Secondary, it is impossible to 
regulate exactly how many copies of the transgene will be introduced into the embryo and 
how many will join together to integrate. In addition, the transgene can insert into functional 
endogenous genes and interrupt the normal expression of them, which may be 
inconsequential or lethal. Alternatively, observable insertional mutagenesis might be 
apparent when the insertion interferes with the expression of an endogenous 
developmentally active gene. Thus the identification of the locus of transgene insertion is of 
great value when analyzing these transgenic animals. 
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Fig 1-8. Generation of transgenic mice through pronuclear injection. The construct 
containing a promoter, the target transgene and a poly A sequence is microinjected to the 
pronuclei of zygotes from donor mice. The injected embryos are transplanted into 
pseudopregnant foster mothers. Fonders are verified and further breed to establish 
transgenic lines. (From http://www.imbim.uu.se) 
 
1.4.3 ES cell-mediated transgenic mice 
ES cells are pluripotent cells derived from the inner cell mass of blastocyst-stage embryos. 
They can be maintained in culture as undifferentiated under the proper growth conditions. A 
broad spectrum of strategies has been designed to create genomic alterations in these cells. 
Homolougous recombination-based gene  targeting, heterologous site-specific 
recombinases (Cre recombinase, Flp recombinase), positive and negative selectable markers, 
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reporters, and the availability of the mouse genome sequence have created an arsenal of 
tools that allow tailoring the mouse genes and genomes at will. When the genetically altered 
ES cells are injected into a host blastocyst, or aggregated within a morula-stage embryo, 
they have the capacity to contribute to all tissues of the resultant chimeric mouse or fully ES 
cell–derived F0 generation mouse (Poueymirou, Auerbach et al. 2007) (Figure 1-9). Most 
important, ES cells can contribute to germ cells and transmit the genetic mutations in vivo, 
allowing development of established mouse lines in which the altered gene(s) are carried.  
ES cell-mediated transgenesis has several advantages over the standard pronuclear DNA 
injection. ES cells make the site specific gene targeting possible. They provide a higher 
frequency of low-copy numbers or even single copy of transgene integration. In addition, 
modified ES cell clones can be tested in vitro for cell type specific expression by ES cell 
differentiation assays. 
 
Figure 1-9. Production of trangenic mice by ES cell-mediated methods. Genetically 
modified ES cells were aggregated to the 8-cell embryos or microinjected into the 
blastocysts. Chimeras could derive from both ways. But it is also possible to generate F0 
generation mice fully derived from ES cells by laser assisted injection of ES cells to 8-cell 
embryos.  
 
1.4.4 The Cre/loxP system 
The Cre protein is a recombinase identified in the P1 bacteriophage, which reacts when it 
recognizes a sequence of 34 base pairs (called loxP) in a segment of DNA (Kilby, Snaith et 
al. 1993) (Figure 1-10). When two loxP sites are oriented in the same direction, the Cre 
recombinase induces the deletion of the DNA segment placed between them. Conversely, if 
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the loxP sites are oriented in opposite direction, recombination induces its inversion. Cre 
recombinase activity does not require a DNA co-factor or particular topology. Moreover, it 
is active in the eukaryote cells (Sauer and Henderson 1988) in vitro and in vivo.   
To take the advantage of the Cre/loxP system to establish conditioned transgenic mice, the 
first step is to create mice carrying alleles in which two loxP sites surround the gene or 
sequence to be studied without disrupting its activity. These mice are then crossed with a 
transgenic mouse expressing the Cre recombinase in a particular cell type. In the resulted 
offsprings, the Cre recombinase promotes the deletion of the sequences located between the 
loxP sites and induces a null mutation in the cell type in which the transgene is expressed. 
So as long as a line of transgenic mice expressing protein Cre in the tissue concerned is 
available, tissue specific transgenic mice can be easily derived (Tsien, Chen et al. 1996; 
Shibata, Kanamaru et al. 1997; Kulkarni, Bruning et al. 1999)  
 
 
Figure 1-10. The Cre/loxP system and its application. The loxP site, symbolized by a 
triangle is a sequence of 34 base pairs composed of palindromic sequences of 13 bp 
separated by a sequence of 8 bp (a). Cre recombinase specifically recognizes this sequence, 
provokes the cleavage in DNA (vertical arrows, a) and induces the recombination of DNA 
between the two loxP sites as illustrated in (b). Recombination could result in gene deletion 
or inversion(c). If the two loxP sites have the same orientation, the DNA region situated 
between these sites is deleted during recombination. If the orientation of the two loxP sites 
is opposed, recombination leads to the inversion of the region comprised between the two 
sites. (Chales Babinet 2001) 
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1.5 Aim of the study 
Siglec-11 is a recently identified CD33-related Siglec. It is identified as a human-specific 
gene expressed in microglia. When considering the features of the CD33-related Siglec 
family and the specific expression pattern of Siglec-11 on tissue macrophages, particularly 
in brain microglia, one can imagine that this evolutionally new Siglec might be developed in 
humans as an important microglial-specific molecule to create an immunosuppressive 
milieu in the CNS. Thus, we were asking the following questions: Is Siglec-11 involved in 
anti-inflammatory signaling in microglia? Does Siglec-11 have anything to do with 
neuroinflammatory diseases such as multiple sclerosis and Alzheimer’s disease?  
To reveal the answer to these questions, we set out to study the function of Siglec-11 in 
microglia. Due to the limitation in acquiring human microglial cell, our functional assay was 
based on mouse cells. First, we aimed to establish a microglial cell model which expresses 
Siglec-11 for functional assays in vitro. Second, functional study of Siglec-11 was focused 
on microglia. Third, the ligand that Siglec-11 might bind was investigated. Fourth, we 
aimed to generate a transgenic mouse model which expresses Siglec-11 specifically in 
microglia and macrophages to study the function of Siglec-11 in vivo.  
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Buffers and Solutions 
10X (0.125M) Phosphate buffered saline (PBS), pH 7.3 
Components Concentration Company 
NaH2PO4*H2O 0.007M Roth, Germany 
NaH2PO4*7H2O 0.034M Roth, Germany 
NaCl 0.6M Roth, Germany 
ddH2O up to 1 liter Roth, Germany 
 
4% Paraformaldehyde (PFA), pH 7.3  
Components Amount Company 
PFA 20g Sigma, Germany 
NaOH 30ml Roth, Germany 
PBS (10X) 50ml  
ddH2O up to 1 liter Roth, Germany 
 
10X TBE buffer 
Components Concentration Company 
Tris-Base 1.78M Roth, Germany 
Boric Acid 1.78M Sigma, Germany 
EDTA 0.04M Roth, Germany 
ddH2O up to 2 liter Roth, Germany 
 
50X TAE buffer (pH 8.5) 
Components 
Amount 
Company 
Tris-Base 242 g Roth, Germany 
Acetic acid 
57.1 ml Sigma, Germany 
0.5 M EDTA 100 ml Roth, Germany 
ddH2O up to 1 liter Roth, Germany 
 
6X Loading buffer 
Components Concentration Company 
EDTA 0.5M Roth, Germany 
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Sucrose 60% Roth, Germany 
Bromphenol Blue 0.04% Sigma, Germany 
Xylene Cyanole 0.04% Sigma, Germany 
Ficol-400 2% Bio-Rad, Germany 
 
1% Agarose gel  
Components Amount Company 
Agarose 0.5g Biozym, Germany 
Ethidium Bromide 1.25µl Roth, Germany 
TBE (1X) 50ml  
 
Reverse transcription (RT) mix  
Components Amount Company 
Total RNA 5µg  
Hexanucleotide Mix (10X) 1µl Roche, Germany 
dNTP mix (10mM) 1µl Sigma, Germany 
DTT mix (10mM) 2µl Invitrogen, Germany 
5X RT 1st Strand Buffer 4µl Invitrogen, Germany 
RT enzyme (200U/ml) 1µl Invitrogen, Germany 
ddH2O up to 20µl Roth, Germany 
 
Real time RT-PCR mix  
Components Amount Company 
cDNA (200ng/µl) 1µl  
SYBR Green Master Mix (2x) 12.5µl Applied Biosystems 
Primer mix (20pmol/µl) 1µl MWG, Germany 
ddH2O 10.5µl Roth, Germany 
 
PCR reaction mix (50 µl ) 
Components Amount Company 
Buffer (10X) 5µl Roche, Germany 
dNTP mix (10mM) 1µl Amersham Bioscience, USA 
Primer pair mix (20 pmol/ul) 2µl MWG, Germany 
Taq polymerase(100U/20ul) 1µl Roche, Germany 
ddH2O Up to 50µl Roth, Germany 
 
Digestion reaction mix (20 µl sample) 
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Components Amount Company 
Buffer (10X) 2µl Roche, Germany 
Enzyme  10 U Roche, Germany 
Plasmid/insert Up to 1 µg 
 
ddH2O Up to 20µl Roth, Germany 
 
Ligation reaction mix (20 µl sample) 
Components Amount Company 
Buffer (10X) 2µl Roche, Germany 
T4 Ligase (1U/ul)  
Or T4 Ligase (2000 1U/µl) 
4 µl 
1 µl 
Roche, Germany 
NEB, Germany 
Plasmid and insert fragment In correct ratio 
 
ddH2O Up to 20µl Roth, Germany 
 
Protein lysis buffer 
Components Concentration Company 
RIPA buffer Cat.no.R2078 Sigma, Germany 
PMSF  1 mM (174 µg/ml) Sigma, Germany 
Aprotinin  5 µg/ml Sigma, Germany 
Leupeptin 5 µg/ml Sigma, Germany 
Phosphatase inhibitors  Sigma, Germany 
Na3VO4  NEB, Germany 
 
Buffers for SDS-PAGE and Western Blot 
Components Cat. No  Company 
NuPAGE LDS Sample Buffer (4x) NP0007 Invitrogen, Germany 
NuPAGE® MES SDS Running 
Buffer (20X) 
NP0002 Invitrogen, Germany 
NuPAGE® Tris-Acetate SDS 
Running Buffer (20X) 
LA0041 Invitrogen, Germany 
NuPAGE® Transfer Buffer (20X) NP0006 Invitrogen, Germany 
BenchMark® Protein Ladder 10747-012 Invitrogen, Germany 
SeeBlue® Pre-Stained Standard LC5625 Invitrogen, Germany 
 
PBS-Tween-20 (PBST) 
Components amount Company 
Tween-20 500 µl  
1x PBS 1000 ml  
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Membrane blocking solution 
Components concentration Company 
BSA 3% Sigma, Germany 
Or Milk powder 5 % Sigma, Germany 
PBST 100 ml  
 
2.1.2 Cell culture media and reagents 
DMEM medium (for MEFs, 293FT cells) 
Components Concentration Company 
DMEM, high glucose  Gibco, Germany 
Fetal bovine serum 10% Gibco, Germany 
Na-pyruvate 0.1mM Gibco, Germany 
L-glutamine 4mM Gibco, Germany 
Non-essential amino acids 0.1mM Gibco, Germany 
Penicillin/Streptomycin (100X) 1% Gibco, Germany 
 
Basal medium  
Components Concentration Company 
BME  Gibco, Germany 
Fetal bovine serum 10% Gibco, Germany 
L-glutamine 1% Sigma, Germany 
D-glucose (45%) 1% Sigma, Germany 
Penicillin/Streptomycin (100X) 1% Gibco, Germany 
 
BME-based neuronal medium  
Components Concentration Company 
BME  Gibco, Germany 
Fetal bovine serum 10% Gibco, Germany 
B-27 2% Gibco, Germany 
L-glutamine 1% Sigma, Germany 
D-glucose (45%) 1% Sigma, Germany 
Penicillin/Streptomycin (100X) 1% Gibco, Germany 
 
Embryonic stem cell (ES) medium  
Components Concentration Company 
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DMEM, high glucose  Gibco, Germany 
Fetal bovine serum 15% Gibco, Germany 
Na-pyruvate 0.1mM Gibco, Germany 
L-glutamine 4mM Gibco, Germany 
Non-essential amino acids 0.1mM Gibco, Germany 
L-alanin-L-glutamine 2mM Gibco, Germany 
β-mercaptoethanol 0.1mM Millipore, Germany 
Leukemia inhibitory factor  1000U/ml Millipore, Germany 
 
RPMI medium  
Components Concentration Company 
RPMI1640  Gibco, Germany 
Fetal bovine serum 10% Gibco, Germany 
 
Macrophage GM-CSF conditioned medium 
Components Concentration Company 
Fetal bovine serum 5% Gibco, Germany 
Supernatant of 5637 cultured medium 45%  
RPMI medium 50%  
 
Other cell culture reagents  
Opti-MEM Gibco, Germany 
Trypsin-EDTA (0.05%) Gibco, Germany 
Chicken serum Gibco, Germany 
Gelantine (0.1%) Sigma, Germany 
Poly-L-lysine Sigma, Germany 
PBS (1X) Gibco, Germany 
Tryptan blue Gibco, Germany 
Normal goat serum Sigma, Germany 
LPS Sigma, Germany 
Recombinant mouse Interferon γ HyCult Biotechnology, Germany  
Fluoresbrite Polychromatic Red Microspheres Polysciences, Germany 
TPA Sigma, Germany 
G418 (neomycin) Sigma, Germany 
M16 and M2 medium Sigma, Germany 
EndoN AbCys S.A, France 
Fluoresbrite polychromatic red 1.0 micron microspheres 
(the beads for phagocytosis assay) 
Polysciences, USA 
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2.1.3 Cells and animals 
Cell Common name Source 
ES-129-MPI MPI  kindly provided by Ahmed 
Mansouri, MPI Göttingen 
ES-Bruce4 Bruce4 kindly provided by Frank Edenhof 
and Anke Leinhaas, RNB, Bonn 
Murine embryonic fibroblasts (MEF) MEF isolated from CD1 mice 
(E14.5);kindly donated by Anke 
Leinhaas 
293FT 293FT Invitrogen, Germany 
Primary murine microglia  Primary microglia isolated from C57Bl/6J newborns 
(p3-5) 
U937 monocytic cell U937 ATCC, Germany 
Human urinary carcinoma cell line 
(ATCC 5637) 
5637 ATCC, Germany 
 
 
Mouse strain Source 
CD1 Charles River Laboratories, Germany 
C57Bl/6J Charles River Laboratories, Germany  
B6D2 F1 Charles River Laboratories, Germany 
 
 
2.1.4 Antibodies 
Primary antibodies  
Antibody Host reactivity Conjugation Company 
CD16/CD32 (FC-Block) rat     BD pharmingen, Germany 
CD45 rat  biotin BD pharmingen, Germany 
Flag mouse   Sigma, Germany 
Flag mouse  Cy3 Sigma, Germany 
IgG1κ isotype mouse   BD pharmingen, Germany 
Whole rabbit serum rabbit   Dianova, Germany 
Siglec-11 goat human Biotin R&D, Germany 
Iba1 rabbit mouse  Wako, Germany 
GFP rabbit mouse  Abcam, Germany 
β III tubulin mouse mouse  Sigma, Germany 
β- actin mouse   Millipore, Germany 
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Biotin IgG1κ isotype mouse  Biotin BD pharmingen, Germany 
 
Secondary antibodies for flow cytometry 
Antibody Reactivity Host Conjugation Company 
PE biotin    streptavidin Dianova, Germany 
Alexa 488  rabbit goat           Invitrogen, Germany 
 
Secondary antibodies for immunostaining 
Fluorophore Reactivity Host Company 
Cy3 mouse goat Dianova, Germany 
Cy3 rabbit goat Dianova, Germany 
Alexa 488  rabbit goat Invitrogen, Germany 
Alexa 488  mouse goat Invitrogen, Germany 
FITC mouse goat Dianova, Germany 
FITC rabbit goat Dianova, German 
FITC- Strepvidin biotin  Dianova, German 
Cy3- Strepvidin biotin  Dianova, German 
 
Secondary antibodies for Western blot 
Antibody Reactivity Host Conjugation Company 
streptavidin biotin  HRP Millipore, Germany 
IgG goat rabbit HRP         Dianova, Germany 
 
Other staining reagents 
DAPI  Sigma, Germany 
Propidium iodide  Sigma, Germany 
 
 
2.1.5 Primer (purchased from MWG, Germany) 
Primers used for real-time PCR 
Target Orientation Sequence 
GAPDH forward 5’- AACTTTGGCATTGTGGAAGG -3’ 
 reverse 5’- GGATGCAGGGATGATGTTCT -3’  
NOS2 forward 5’- AAGCCCCGCTACTACTCCAT -3’ 
 reverse 5’- GCTTCAGGTTCCTGATCCAA -3’ 
TNF-α forward 5’- TCTTCTCATTCCTGCTTGTGG -3’ 
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 reverse 5’- AGGGTCTGGGCCATAGAACT -3’ 
IL-1β forward 5’- CTTCCTTGTGCAAGTGTCTG -3’ 
 reverse 5’- CAGGTCATTCTCATCACTGTC -3’ 
TGF-1β forward 5’- CAATTCCTGGCGTTACCTTG -3’ 
 reverse 5’- GCTGAATCGAAAGCCCTGTA -3’ 
 
Primers used for cloning 
Target Orientation Sequence 
Eco47III_XhoI_Siglec-11 
forward 5’-ATATTAGCGCTCTCGAGGCCACCATGC
TGCTGCTGCCCCTGCTGCT -3’ 
EcoRI_Siglec-11 
reverse 5’-CCGGGTGAATTCTTCGAATCATCACTT
TGGAACCATCCCTGACATCCCTG -3’ 
SfuI_4Gly_Siglec-11 
reverse 5’-ATTTCGAATCCTCCTCCTCCTCCTCCCT
TTGGAACCATCCCTGACATCTC -3’ 
 
Primers used for RT-PCR of Siglec-11 
Primer pair Orientation Sequence 
1 forward 5’-TCTCAGCCTCTCCGTGCACT-3’ 
 reverse 5’-CAAGGCAGGAACAGAAAGCG-3’ 
2 forward 5’-ACAGGACAGTCCTGGAAAACCT -3’ 
 reverse 5’-AGGCAGGAACAGAAAGCGAGCAG -3’ 
3 forward 5’-TGCTACCAGGGAAGCTGGAGCAT -3’ 
 reverse 5’-AGGCATAGTGGAGCTCCTGCTCTT -3’ 
 
Primers used for sequencing 
Target Orientation Sequence 
Siglec-11 forward 5’-CCTGAGCAATGCGTTCTTTC-3’ 
  5’-ACAGGACAGTCCTGGAAAACCT-3’ 
  5’-TGCTACCAGGGAAGCTGGAGCAT-3’ 
 reverse 5’-ATAAGCAGCAGTAGACTCGTCC-3’ 
  5’-AACACACAGATGACCGTCACCG-3’ 
  5’-AGGCAGGAACAGAAAGCGAGCAG-3’ 
  5’-AGGCATAGTGGAGCTCCTGCTCTT-3’ 
PLL backbone reverse 5’-GGGTACAGTGCAGGGGAAAGAATAGTAG-3’ 
Iba1 promoter forward 5’-ATCGATTACTATAGGATGCATCGTG-3’ 
  5’-GGGAGTTAGCAAGGGAATGAGT-3’ 
  5’-CAAGGCTATCCCTGGTATGAG-3’ 
  5’-CTCCGGGAGCTGATCTAAGTCTTTC-3’ 
 reverse 5’-CTCATACCAGGGATAGCCTT-3’ 
  5’-GTGTGGAAAGGCACCAGGAT-3’ 
  5’-CTGAACTTGTGGCCGTTTAC-3’ 
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  5’-GTTTCCTGTTTGCAGGGTACAC-3’ 
CMV promoter forward 5’-AAAATGTCGTAACAACTCCG-3’ 
PGK promoter forward 5’-TAGCACGTCTCACTAGTCTCG-3’ 
 reverse 5’-GCGAAGGAGCAAAGCTGCTATT-3’ 
Neo forward 5’-GGCTATGACTGGGCACAACAG-3’ 
  5’-GATGATCTCGTCGTGACCCATG-3’ 
  5’-TTTCTCGGCAGGAGCAAGGT-3’ 
 reverse 5’-TTTCTCGGCAGGAGCAAGGT-3’ 
GFP forward 5’-ACGTAAACGGCCACAAGTTCAG-3’ 
  5’-ACCACTACCAGCAGAACACC-3’ 
 reverse 5’-TGCAGATGAACTTCAGGGTCAG-3’ 
 
2.1.6 Consumables 
6-well culture plates Cellstar, VWR International, Germany 
15ml tubes Cellstar, VWR International, Germany 
50ml tubes Sarstedt, Germany 
5ml, 10ml, 25ml pipets Sarstedt, Germany 
Chamber slides Nunc, Germany 
Cryovials VWR International, Germany 
75cm2, 175 cm2  culture flasks Sarstedt, Germany 
5ml polystyrene round-bottom tubes BD Falcon, Germany 
3cm, 5cm, 10cm culture dishes Sarstedt, Germany 
500µl, 1000 µl plastic tube Eppendorf, Germany 
PCR tubes Biozym Diagnostics, Germany 
10µl, 100µl, 1000µl tips Eppendorf, Germany 
5ml, 10ml syringes Braun,Germany 
Needles Braun, Germany 
Glass slides for cryosectioning Menzel, Germany 
Bottle top filters (0.25µm pore) Millipore, Germany 
Filters (0.45µm, 0.2µm pore) Sarstedt, Germany 
Transwell (8µm pore filter) Millipore, Germany 
 
2.1.7 Equipment 
Centrifuges Sorvall Discovery 90SE, Hitachi, Germany   
Megafuge, 1.OR. Heraeus, Germany   
Biofuge Fresco, Heraeus, Germany 
Cryostat Microtom HM560, Microm Int., Germany 
Flow cytometer FACSCalibur, BD Bioscience, Germany 
Electrophoresis gel chambers Blomed Analytik GmbH, Germany 
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Power supply Amersham Bioscience, Germany 
Heating block Stuart Scientific, Germany 
Incubators Heracell240, Heraeus, Germany 
Laminar air flow workbench Herasafe, Heraeus, Germany 
Microscopes Axiovert40CFL, Zeiss, Germany       
 Axiovert200M, Zeiss, Germnay 
 Fluoview1000 Confocal Microscope, Olympus, 
Germany 
 Olympus SZXZ-ILLT, Olympus corporation, Japan 
pH Meter Hanna Instruments, Germany 
Photometer Eppendorf, Germany 
Real time thermocycler ABI Prism 5700 Seqeunce Detection System, 
Applied Biosystems, UK 
Thermocycler T3, Biometra, Germany 
Vortex 2X2, VelpScientifica, Germany  
Transplantationsequipment Fine Science Tools, Germany 
 
2.1.8 Software 
Openlab4.0.1  Improvision, Germany 
CorelDRAW Graphics Suite 11, Germany 
EndNote X Thomson ISI ResearchSoft, USA 
Microsoft Office Microsoft USA, USA 
Olympus FluoView1.4 Olympus, Germany 
SDS 2.2.2 Applied Biosystems, USA 
Cellquest Pro BD Biosciences, USA 
FlowJo 6.4.7 Tree Star, USA 
KaleidaGraph 4.0 Synergy, USA 
SPSS 16.0 SPSS, USA 
Axiovision 4.6.3 Carl Zeiss Imaging Solutions, Germany 
ImageJ 1.39u NIH, USA 
CorelDRAW Graphics Suite 12, USA 
Vector NTI Advance 10 Invitrogen, USA 
Gene Runner Hasting Software, Inc. USA 
Primer Premier 5.0 Premier Biosoft International, USA 
 
                                                     Materials and Methods 
 48 
2.1.9 Kits and additional reagents 
RNA and DNA isolation kit 
RNeasy Mini Qiagen, Germany 
RNeasy Mini for lipid tissue Qiagen, Germany 
RNAse free DNAse Kit Qiagen, Germany 
QIAprep Plasmid Miniprep Qiagen, Germany 
Endofree Plasmid Maxiprep Qiagen, Germany 
Min iElute Gel extraction Qiagen, Germany 
QIAquick Gel extraction Qiagen, Germany 
Red Extract-N-Amp Tissue PCR Kit Sigma, Germany 
 
Additional reagents 
Lipofectamine2000 reagent Invitrogen, Germany 
Ampicilin Sigma, Germany 
LB agar and LB media Fluke Biochemika 
DMSO Sigma, Germany 
Propidium Iodide Sigma, Germany 
Glycerol Sigma, Germany 
Tissue tek O.C.T. compound Sciences Services, Germany 
Ethanol Sigma, Germany 
Vectashield Vector Laboratories, USA 
Bovine serum albumin Sigma, Germany 
Hexamer random primers  Roche, Germany 
Trizol Reagent Invitrogen, Germany 
 
2.1.10 Anesthethics 
Animals were anesthetized with Ketamin intraperitoneal (i.p.) (Ketamin 100 mg per kg 
body weight) before embryo transplantation or perfusion.   
 
2.2 RT-PCR analysis of Siglec-11  
RNA was isolated from human brain tissue derived from patients undergoing epilepsy 
surgery (kindly provided by the Department of Neurosurgery and Epileptology of the 
University Hospital Bonn) using RNeasy Mini for lipid tissue Kit or from cultured cells 
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using Trizol Reagent. Reverse transcription of RNA was performed with SuperScript III 
reverse transcriptase and hexamer random primers using 5µg total mRNA. Primer pairs 
designed according to the coding region of Siglec-11 gene were used to detect the 
expression of Siglec-11. PCR was amplified for 40 cycles. Amplified product was 
electrophoresed on 1% agrose gel. 
 
2.3 Plasmids construction 
PLL3.7 (provided by L. van Parijs, MIT, Cambridge, MA) was modified to contain a 
neomycin selection marker by replacing the U6 promoter with a cassette of 
phosphoglycerate-kinase (PGK) promoter and neomycin resistant gene. Plasmids 
expressing GFP (Invitrogen), Siglec-11 (RZPD, Deutsches Ressourcenzentrum fuer 
Genomforschung GmbH), flag and GFP tagged Siglec-11 were cloned based on the 
modified pLL3.7 back bone behind a cytomegalovirus (CMV) promoter. In some cases 
the CMV promoter was replaced by ionized calcium-binding adaptor molecule 1 (Iba1) 
promoter. Described genes or fragment were obtained from corresponding constructs by 
PCR using extended primers allowing the product to be inserted into the following vectors 
by specific restriction sites. Digested vector backbone and insert were ligated and 
transformed to Top10 competent cells. Positive colonies selected by antibiotics were 
inoculated in a small volume. Plasmid DNA was isolated and restrictively digested using 
the corresponding enzymes. Colonies having the insert were expanded and purified using 
EndoFree Maxi Kit (Qiagen,Germany). The sequence of each plasmid was verified 
further by sequencing. 
 
2.4 Viral particle production 
The 293FT (purchased from Invitrogen and expanded in the laboratory) packaging cell 
line was kept in Dulbecco's Modified Eagle's Medium (DMEM; Gibco) with 1% 
penicillin/streptomycin and glucose at 37°C in 10% CO2. Viral particles were produced in 
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10 cm dishes precoated with poly-L-Lysine. Three µg of targeting plasmid together with 
3µg of each of the three packaging helper plasmids were co-transfected using 
Lipofectamine 2000 reagent (Invitrogen) to 6 million 293FT cells, which were expanded 
at least once before transfection. Cells were transfected in Opti-MEM medium without 
antibiotics containing 10% FBS. Medium was replaced by fresh DMEM 6 to 16 hours 
post-transfection. Viral supernatant (10 ml) was collected at 48-72 hrs post-transfection. 
Viral particles were then ultracentrifuged using a Sorvall DiscoveryTM 90SE 
ultracentrifuge at 25000 g (19600 rpm) for 90 min at 4°C to increase titers. Concentrated 
viral particle pellet were resuspended in 300 µl PBS by slightly shivering overnight at 4°C. 
Viral particles were either immediately applied to transduce cells or stored at -80°C in 
small aliquots for further usage. 
 
2.5 Lentivial transduction of cells 
To transduce adherent cells, cells were normally seeded at a density of 5x105cells/ml in 
6-well dish and incubated overnight to 24 hours with 108 Transducing Units (TU)/ml of 
lentiviral particles (50 µl viral particle per ml medium).  
To transduce cells in suspension, viral particles were added to 5x105cells/ml cells in 
6-well dish and first centrifuge at 2400 rpm, 32°C for 90 min. After centrifugation step, 
cells were kept in 37°C and 5% CO2 incubator. 24 hours post-transduction, medium were 
refreshed into complete culture medium. In cases to enrich the positively transduced cells, 
neomycin (also know as G418) selection was applied at a concentration of 400 to 1000 
µg/ml (according to the cell killing curve of different cell types) from 48 hours 
post-transduction for 5 days. 
To transduce mouse ES cells, cells were plated at a density of 3 x105cells/well in 6-well 
dish with MEF feeders. Six hours later, when the ES cells were attached but still in 
single-cell condition, the medium was refreshed with 50 µl viral particle in 1 ml medium 
and incubate for 24 hours. Medium was changed afterwards and cells were spilt into 10 
cm dish 48 hours post-transduction. G418 was applied then as to the other cell types for 
10 days at a concentration of 230 µg/ml. Single ES cell colony surviving the selection 
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were picked out manually to 96-well plate with MEF feeder cells. After verifying the 
incorporation of the target gene by PCR, the positively transduced colonies were 
expanded and used for further experiments.  
 
2.6 PCR analysis of the incorporation of the lentiviral vector to the 
transduced cells 
Genomic DNA was isolated from the cells using QIAmp DNA Mini Kit. GAPDH was 
used as a positive control for the quality and quantity of DNA. Primers specific for 
Siglec-11 gene were used to detect the incorporation of the gene to the genome of the 
target cells. PCR was amplified for 40 cycles. Amplified DNA was electrophoresed on 
1% agrose gel.  
  
2.7 Culture of primary microglia 
Primary microglia were prepared from brains of postnatal day 3 or 4 (P3 or P4) of 
C57BL/6 mice. In brief, meninges were removed mechanically. Cells from hippocampus 
and cortex were isolated and dissociated by triturating and cultured in basal medium for 
14 days to form a confluent mixed glial monolayer. To collect microglial cells, the 
cultures were shaken on a rotary shaker (350 rpm) for 3 hours. The detached microglial 
cells were seeded on PLL coated culture dishes. Purity of the isolated microglia was 
determined by flow cytometry analysis with antibody directed against CD11b.  
 
2.8 Culture of 5637 cell line (human urinary bladder carcinoma)  
5637 is a growth factor producing cell line established from a human primary bladder 
carcinoma. The supernatant of the cell line was used as a substitute for the rhGM-CSF. 
The cells were cultured in tissue culture flasks in RPMI medium at 37°C with 5% CO2. 
Confluent cells were split in a 1:5 ratio. The supernatant of the cell line was collected 
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every 3rd days. Dead cells and cell debris were removed from the supernatant by 
centrifuging for 10 minutes at 1000rpm. The supernatant was then passed through a 
0.2µm filter and used as a substitute for rhGM-CSF to prepare macrophage GM-CSF 
conditioned medium.  
 
2.9 Culture and differentiation of human monocytic cell line 
The human monocytic cell lines U937 (ATCC, Germany) was maintained in RPMI 
medium supplemented with 10% FBS. New cultures of 2x105/ml were made when the 
cell density was about 10x 105/ml. To differentiate the suspending cells into macrophages, 
cells were treated with 200 ng/ml of TPA (Sigma, Germany) in macrophage GM-CSF 
conditioned medium for 24 hours. Attached cells were further maintained in macrophage 
GM-CSF conditioned medium. Trypsin was applied to detach the cells from the dish 
when necessary.  
 
2.10 Culture of ES cells 
One or two days before starting the culture of ES cells, irradiated MEF feeders were 
prepared in tissue culture plates pre-coated with gelatin (0.1%) at a density of 0.5x 105 
cells/cm2 to form a monolayer. ES cells were seeded to the feeder cultures at a density of 
3 x 106 cells / 100 mm plate in ES culture medium, kept at 37°C with 5% CO2. The cells 
were examined and media was changed daily. To split the cells, 0.25% trypsin-EDTA was 
used for MPI ES cells (MPI, Göttingen), while 2% of chicken serum was added to the 
0.25% trypsin-EDTA when splitting the Bruce4 ES cells (Frank Edenhof and Anke 
Leinhaas, Bonn).   
 
2.11 Immunocytochemistry of cultured cells 
Cells were fixed in 4% PFA for 15 min at room temperature (RT), blocked by 5% bovine 
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serum albumin (BSA), 5% normal goat serum (nGS) and 0.1% Triton-X for 30 min, and 
then immunostained with a primary antibody diluted in the blocking solution at the right 
concentration for overnight at 4°C or for 1 hour at RT. A chromophore-conjugated 
secondary antibody was prepared in blocking solution and applied to the cells at RT for 1 
hour. Double-labeling was performed by mixing the primary antibodies from different 
producer species followed by chromophore-conjugated secondary antibodies that could 
avoid the overlap of emission length. For example Cy3 (3 µg/ml) /Alexa488 (2.5 µg/ml) 
combination were used. Nuclei of immunostained cells were subsequently labeled with 4', 
6-diamidino-2-phenylindole (DAPI) (0.1 µg/ml). Images were collected by confocal laser 
scanning microscopy (Fluoview 1000, Olympus) or fluorescence microscopy (Axioskop2, 
Zeiss). 
 
2.12 Analysis of cytokine gene transcripts by real-time RT-PCR 
RNA was isolated with the RNeasy Mini Kit from 0.5 x 105 primary microglia after 
stimulation with 500ng/ml LPS for 24 hours. Reverse transcription of RNA was 
performed with SuperScript III reverse transcriptase and hexamer random primers. 
Quantitative RT-PCR with specific oligonucleotides was performed with SYBR Green 
PCR Master Mix using the ABI 5700 Sequence Detection System and amplification 
protocol for the ABI 5700 Sequence Detection System. Amplification specificity was 
confirmed by the analysis of the melting curves. Results were analyzed with the ABI 5700 
Sequence Detection System v.1.3 after establishing the reaction efficiency for each primer 
pair. Quantification using the delta-CT method was carried out. 
 
2.13 Western blot analysis of the protein expression 
Total protein was isolated from human brain tissue using Trizol Reagent, followed by  
chloroform，ethanol and isopropanol precipitation. Briefly, the tissue was homogenized in 
Trizol Reagent at 1ml per 1mg tissue. Chloroform was added to the homogenate to 
separate it into aqueous and organic phases after centrifugation. The interphase and the 
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organic phase contained DNA and proteins. Sequentially DNA was precipitated with 
ethanol. Proteins were isolated from the phenol-ethanol supernatant obtained after 
precipitation of DNA and washed with 3 times of 0.5 ml of 0.3 M guanidine 
hydrochloride in 95% ethanol and one time of 100% ethanol. The protein pellet was then 
resuspended in 1% SDS and stored at -80 0C. To prepare protein lysate from cultured cells, 
cells in culture dish were rinsed once with PBS at RT. RIPA buffer (Sigma, 107cells/ml) 
was added to homogenize the cells on ice. Adherent cells were further removed with a cell 
scraper. The resulting lysate was transfered to a microcentrifuge tube and gently rocked at 
4° C for 15 minutes. Afterwards, cell lysate was centrifuged at 10,000 g for 10 minutes at 
4° C. The supernatant was collected to a new microcentrifuge tube as the whole cell lysate.  
Protein concentration was measured using the BCA Kit from Thermo Scientific Pierce 
Protein Research Products. 50 µg of protein was loaded to 10% NuPAGE® Novex 
Bis-Tris Gels. SDS-PAGE was carried out using the NuPAGE® Electrophoresis System 
according to the manufacture. Biotinylated anti-Siglec-11 antibody and anti-β-actin 
antibody was used at 0.2 ug/ml and followed by proper secondary antibody to blot the 
target proteins. Antibody binding was visualized with SuperSignal West Pico 
Chemiluminescent Substrate Kit (Pierce Biotechnology). 
 
2.14 Removal of PSA by EndoN treatment 
EndoN (AbCys S.A, France) was diluted in the medium of the culture at a concentration 
of 0.5 U/ml and added to the cells. Cells were incubated at 37oC for at least 5 hours. 
 
2.15 Microglia-neuron co-culture 
Primary neuronal cultures were prepared from hippocampus and cortex of C57BL/6 mice 
embryos (E15) as described previously (Neumann H. et al, 2002). Briefly, neurons were 
isolated from whole brains of embryonic day 16 mice, and the meninges were removed. 
Cells (5 x 103/ml) were plated into dishes that had been pre-treated with poly-L-ornithine 
(0.5 mg/ml; Sigma, St. Louis, MO) and were cultured in BME-based neuronal medium. 
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Neurons at day 4 post-preparation were used to co-culture with micrglial cells. Microglia 
were added to the neuron culture at the ration of 1:10 (micorglia to neuron) in the 
BME-based neuronal medium. 48 hours later, cells were fixed with 4% PFA at RT for 15 
minutes.  
 
2.16 Neurite and neuroal cell body evaluation 
Immunocytochemistry was performed after fixation with 4% PFA. Cells were stained 
with β-tubulin-III antibody followed with Cy3 conjugated secondary antibody and 
subsequently DAPI labeling of the neulei. Five randomly selected areas in each dish were 
scanned and analyzed by confocal microscopy. β-tubulin-III positive neuritis, which 
crossed two of four 500-µm-long parallel lines (distance of 100 µm), were counted. Total 
number of nuclei stained with DAPI and double labeled with antibodies directed against 
β-tubulin-III was counted in five microscopic fields. Value of the co-cultures with 
Siglec-11 expressing microglia was normalized to that of the the co-cultures with control 
vector expressing microglia. 
 
2.17 Aβ phagocytosis assay 
Biotinylated Aβ 42 peptide was kept at RT to allow the formation of aggregates. To 
analyze the phagocytosis capacity, cells were treated with Aβ (10 µg/ml) for 1.5 hour. 
Cells were fixed in 4% PFA and then permeabilized with 0.1% Triton X-100. Fixed cells 
were stained with Cy3-conjugated streptavidin. Microglial cells were visualized by 
staining of CD45 antibody followed with the FITC conjugated secondary antibody. 
Analysis was made using fluorescence microscopy. 5 photographs were taken of each 
well and cells emitting a yellow signal were classified as phagocytosing and counted 
accordingly. 
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2.18 Generation of transgenic mice from embryo-stem cell 
aggregation 
CD-1 mice were used as embryo donors. 4-week old CD-1 femals (Charles River) were 
superovulated by administering intraperitoneally pregnant mare’s serum (PMS), which is 
used to mimic follicle-stimulating hormone (FSH), and 47 hours later human chorionic 
gonadotropin (hCG), which is used to mimic luteinizing hormone (LH), each at a dose of 
5 IU/mice. The females were then mated with stud males. Next, females with a copulation 
plug were picked out for embryo collecting. 8-cell stage embryos were collected from 2.5 
days post-coitum (dpc) females. The zona pellucida of the embryos was removed using an 
acidic tyrode solution. Small drops (50 µl) of M16 medium (Sigma) were placed on the 
bottom of a 60-mm sterile plastic culture dish. Six or more depressions in each microdrop 
were punched with aggregation needles. Zona pellucida free embryos were washed 3 
times in M2 medium and transferred into these microdrops, one embryo inside each 
depression. ES cells lentiviral transduced with Siglec-11 and positively picked by PCR 
analysis were trypsinized for short time (1 minute) to detach from the culture dish but 
avoid dissociating them into single cells. ES cell clumps formed after incubating in M2 
medium on ice for 20 minutes. Clumps with around 16 ES cells in each were placed on 
the top of the embryo in a depression in the microdrop. The aggregates were culture 
overnight at 37o C, 5% CO2. The next day, 10-15 blastocyts and/or compact morulas were 
transferred into one uterine horn of each 2.5 dpc pseudopregnant recipient CD-1 mouse. 
Chimerical mice with 30% or more ES cell derived coat color were breed with CD-1 mice 
at age of 6 weeks to check for germ-line transmission.  
 
2.19 Generation of transgenic mice from pronuclear injection 
The pronuclear injection experiments were carried out in HET (Haus für Experimentelle 
Therapie) by the facility. For the pronuclear injection, the Iba1 promoter, cDNA of 
Siglec-11, together with WPRE cassette were separated from the vector by NotI and BsiEI 
digestion followed by 1% agrose gel electrophoresis. DNA fragment was isolated from 
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gel using the QIAquick Gel extraction kit (Qiagen) according to the manufacture’s 
instructions and supplied to the facility upon request. Otherwise, DNA was stored at a 
concentration of about 100ng/ul at -80 o C. 3-5 ng/µl of DNA was used to inject into E0.5 
zygotes collected from superovulated femal zygotes donors and transferred to 
pseudopregnant recipient CD-1 mouse according to established procedures. Newborns 
were genotyped at age of 2 to 4-week by PCR of DNA from the tail tip using primer pair 
3 of Siglec-11. Founders with the transgene were further breed to establish germ-line 
transmitting lines. 
 
2.20 Genotyping of mice 
Mouse tail tips were cut at the age of 2 to 4 weeks. DNA was prepared using the Red 
Extract-N-Amp Tissue PCR kit (Sigma) according to the manufacture’s instruction. PCR 
reaction was carried out using the Siglec-11 specific primers with 40 cycles. Amplified 
DNA was electrophoresed on 1% agrose gel. 
 
2.21 Statistics 
Data are presented as mean ± SEM of at least 3 independent experiments. Data were 
analyzed by ANOVA using SPSS computer software. 
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3 RESULTS 
3.1 Detection of splice variant 2 of Siglec-11 in human brain tissue  
In order to confirm the expression of Siglec-11 in human microglia, we analyzed human 
brain tissue by RT-PCR. In literature, it is described that Siglec-11 consists of 11 exons 
separated by introns. Three distinct primer pairs derived from different exons of Siglec-11 
gene were designed (Table 3-1) to check the transcription of Siglec-11. Human brain 
tissue was kindly provided by the Department of Neurosurgery and Epileptology of the 
University Hospital Bonn and was derived from patients undergoing epilepsy surgery. 
Total RNA was isolated freshly from three human brain tissue samples. Reverse 
transcription was carried out immediately afterwards to avoid any degradation of RNA. 
Siglec-11 was detected in all the samples tested (Figure 3-1). However, the detected gene 
product was 288 bp shorter than the product that was firstly described in literature. 
Further analysis showed that the amplified gene product was derived from the second 
splice variant of Siglec-11 (Clark, H.F. et. al., 2003). This variant 2 of Siglec-11 lacks one 
exon (exon 8 as indicated in Figure 3-1), which is coding one out of the five Ig-like 
domains (the Ig-like domain 5) in the extracellular part. 
Table 3-1. Primers used for RT-PCR analysis of Siglec-11 
Primer pair Orientation Product size (bp) 
Forward: 5’-TCTCAGCCTCTCCGTGCACT-3’ 
1 
Reverse: 5’-CAAGGCAGGAACAGAAAGCG-3’ 
103 
Forward: 5’-ACAGGACAGTCCTGGAAAACCT -3’ 
2 
Reverse: 5’-AGGCAGGAACAGAAAGCGAGCAG -3’ 
352 
Forward: 5’-TGCTACCAGGGAAGCTGGAGCAT -3’ 
3 
Reverse: 5’-AGGCATAGTGGAGCTCCTGCTCTT -3’ 
294 
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Figure 3-1. Detection of splice variant 2 of Siglec-11 in human brain tissue by 
RT-PCR. A: cDNA and protein structure of Siglec-11 as first reported by Angata T., et.al. 
The arrows show the sites of the forward and reverse primers used to detect the Siglec-11 
gene expression corresponding to the protein and cDNA. Three different human brain 
tissues were checked. RNA from the human brain tissue and cDNA from mouse brain 
tissue were used as negative control.  
 
To confirm the expression of Siglec-11 at protein level, Western blot analysis was carried 
out. Total protein isolated from three human brain tissue samples was analyzed. Protein 
lysate from 293 cells lentivirally transduced with or without the splice variant 2 of 
Siglec-11 was used as control. Results showed that Siglec-11 expression was detected in 
all the three samples (Figure 3-2). Furthermore, the protein size of the human brain 
samples was the same compared to the one in 293 cells, indicating that in these human 
brain samples the variant 2 of Siglec-11 was predominately expressed. 
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Figure 3-2. Detection of splice variant 2 of Siglice-11 in human brain tissue by 
Western blot. Three different human brain tissues were analyzed. Protein lysates from 
293 cells transduced with or without Siglec-11 were used as negative and positive control. 
 
3.2 Induction of Siglec-11 in macrophages differentiated from 
human monocytes 
It was reported that Siglec-11 was detected in human tissue macrophages but not in 
peripheral blood cells. Monocytes in the blood circulation have the ability to differentiate 
into tissue macrophages. Therefore, we checked whether Siglec-11 can be induced in 
macrophages differentiated from monocytes. The human monocytic cell line U937 was 
differentiated into macrophages by stimulation with 200 ng/ml TPA 
(12-O-tetradecanoylphorbol-13-acetate) for 24 hours. Afterwards, the differentiated cells 
were treated with either LPS or INF-γ for 48 hours and RNA was subsequently isolated. 
RT-PCR showed that Siglec-11 was not detected in undifferentiated monocytes, but was 
detectable in the differentiated macrophages (Figure 3-3). However, the expression levels 
of Siglec-11 were quite low and undetectable by flow cytometry analysis (data not 
shown). 
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Figure 3-3. Induction of Siglec-11 in macrophages. The human monocytic cell line 
U937 was differentiated into macrophages and analyzed by RT-PCR. 
 
3.3 Lentiviral expression of Siglec-11 
3.3.1. Molecular cloning of the lentiviral vectors 
Siglec-11 was tagged with three time flag at the C-terminal and GFP at the N-terminal 
which was shortly termed as fSiglec-11-GFP. In detail, the CMV-3xflag cassette was 
obtained from pReceiver-M12a (RZPD, Germany) by PCR which added the restriction 
sites of NotI and EcoR47III to replace the CMV promoter in the PLL3.7 vector by 
subcloning. Then, the Siglec-11 gene lacking the stop codon was subcloned in front of the 
GFP using the SfuI and EcoR47III restriction sites. Four times of GGA bases were added 
by PCR to make a 4-time glycine linker between the Siglec-11 and GFP protein. 
Siglec-11 tagged with or without GFP under the control of CMV promoter (shortened as 
CMV-Siglec-11-GFP and CMV-Siglec-11) was modified on the basis of fSiglec-11-GFP 
by removing the flag tag and GFP tag in subcloning.  
Siglec-11 tagged with or without GFP was also cloned to the PLL3.7 lentiviral vectors 
under the control of Iba1 promoter using similar strategies.  
All these vectors were also having a PGK-Neomycin selection marker in front of the 
Sigelc11 related expression cassette. All transgenes and their associated promoters were 
flanked by two loxP sites (Figure 3-4). 
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CMV promoter/enhancer
CMV promoter
pUC
LoxP
LoxP
AfeI (4704) XhoI (3960)
XbaI (2617)
NotI (4075)
 
 
 
Figure 3-4. Sketch map of the lentiviral vectors. Top: schematic map of 
PLL-PGK-Neo-CMV-GFP. Bottom: all cloned lentivral vectors to over-express Siglec-11 
tagged or non-tagged with flag and/or GFP under different promoters in the backbone of 
PLL-PGK-Neo-CMV-GFP. 
 
Pcmv Siglec-11 
Piba1 Siglec-11 GFP 
Piba1 Siglec-11 
Pcmv Siglec-11 GFP 
Pcmv Siglec11 GFP 3xflag Pcmv 
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3.3.2 Verification of Siglec-11 expression in 293 cells 
The efficiency of the vectors was tested in 293 cells except the vectors in which the 
transgene was under the Iba1 promoter, which is known as a microglial specific promoter. 
293 cells were lentivirally transduced with the corresponding vectors, and stained with 
anti-Siglec-11 antibody followed by flow cytometry analysis. Results showed that the 
transduced 293 cells were positively stained indicating that all three vector variants 
(fSiglec-11-GFP, Siglec-11-GFP and Siglec-11) led to an expression of Siglec-11 on the 
cell surface (Figure 3-5). However, the efficiency of the vectors differed. Transduction of 
293 cells with fSiglec-11-GFP (17.3%) was less effective compared to Siglec-11-GFP 
(98.3%) and Siglec-11 (97.5%).  
Transduced 293 cells were further analyzed by immunofluorescent staining with 
anti-Siglec-11 antibody. Siglec-11 was detected on the cell surface of 293 cells after 
lentiviral transduction (Figure 3-6). 
 
 
Figure 3-5. Verification of Siglec-11 expression in 293 cells. Representative flow 
cytometry results showed that Siglec-11 was expressed in 293 cells after lentiviral 
transduction.  
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Figure 3-6. Immunocytochemistry of 293 cells after lentiviral transduction with 
Siglec-11. Cells were transduced with CMV-Siglec-11 vector and stained with 
biotinylated anti-Siglec-11 antibody followed by Cy3 conjugated secondary antibody. 
Scale bar: 50 µm.  
 
3.3.3 Transduction of primary mouse microglia 
Primary mouse microglia were isolated from glial cultures which were derived from 
neonatal mice. Cells were transduced with lentiviral vectors by centrifugation for 90 
minutes. The expression of Siglec-11 was verified by RT-PCR using the Siglec-11 
specific primer pair 3 (Figure 3-7). 
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Figure 3-7. Verification of the expression of Siglec-11 in mouse primary microglia. 
Primary mouse microglia were transduced with fSiglec-11-GFP, CMV-Siglec-11 and 
Iba1-Siglec-11-GFP. RT-PCR was carried out using the Siglec-11 specific primer pair 3.  
 
 
3.4. Functional analysis of Siglec-11 in primary microglia  
3.4.1 Cytokines profile after antibody cross-linking of fSiglec-11 in 
primary microglia 
Primary microglia were isolated from mixed glial culture and transduced with lentiviral 
particles to overexpress fSiglec-11-GFP or GFP. Afterwards, cells were stimulated with 
flag antibody or isotype control antibody for 48 hours in combination with or without LPS 
treatment. Cytokine profile was analyzed by real-time PCR. Values collected from cells 
after LPS stimulation were normalized to those of without LPS stimulation. Cross-linking 
with the flag antibody inhibited the expression of IL-1β and NOS2 in Siglec-11 
transduced primary microglial cells (1.81±0.11 and 1.21±0.59, n=4) when compared to 
the control vector transduced cells (28.375±3.53 and 7.06±2.39, n=4). While there was no 
significant difference observed on the relative expression level of TGF-β1 and TNF-α 
(0.69±0.07 and 1.22±0.75 in fSiglec-11-GFP cells versus 1.03±0.15 and 3.85±0.88 in 
GFP cells, n=4) (Figure 3-8).  
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Figure 3-8. Cytokine profile after antibody cross-linking of fSiglec-11 in primary 
microglia. Primary murine microglial cells were lentivirally transduced with 
fSiglec-11-GFP vector or GFP vector. Transduced cells were cultured on plates pre-coated 
with antibodies directed against the flag-tag or a control antibody and stimulated with or 
without 500 ng/ml LPS. Gene transcripts of microglial cells were studied after 48 hours of 
culture by real-time RT-PCR. The values of the LPS stimulated cells were normalized to 
those of the cells without LPS stimulation. Data are shown as means +/- SEM, n=4. * P﹤
0.05. 
 
3.4.2 Aβ phagocytosis assay of Siglec-11 expressing primary microglia 
To investigate whether Siglec-11 has a role in Aβ phagocytosis, primary microglia were 
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transduced with Siglec-11 or the control vector. 48 hours post-transduction, Aβ was added 
to the cells for 1 hour. Cells were then fixed and visualized by staining of CD45-FITC and 
Aβ-Cy3. The percentage of phagocytosing cells out of the total cells captured in one 
visual field was calculated. Data showed that Siglec-11 transduced cells had a significant 
lower ratio of phagocytosing cells (44.17±10.1%) when compared to control cells which 
had 60.77±5.4% of the cells phagocytosing (Figure 3-9).  
 
Figure 3-9. Aβ phagocytosis assay of primary microglia transduced with Siglec-11 or 
control vector. A. Siglec-11 transduced cells. B. Control vector transduced cells. C. A 
representative confocal picture showing microglial cells phagocytosing Aβ peptides. D. 
Statistical analysis showed less Aβ phagocytose in Siglec-11 transduced microglia 
compared to control vector transduced cells. * P﹤0.05, n=4. 
 
3.4.3. Co-culture of Siglec-11 transduced microglia and primary neurons 
Microglia are known for their ability to control the death and synaptic properties of 
neurons (Alain Bessis, 2007). To investigate whether Siglec-11 plays a role in  
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neuron-microglia interactions, microglia were transduced with Siglec-11 vector and 
co-cultured with neurons. It has been shown that Siglec-11 binds weakly but specifically 
to α-2–8-linked sialic acids (NeuAc-alpha 2-8) (Angata, 2002). While the natural ligand 
of Siglec-11 is unknown yet, polysialic acid (PSA), which is present prominently in the 
nervous system, emerges as a possible ligand candidate for Siglec-11. PSA is the linear 
homopolymers of α-2, 8-linked Nacetylneuraminic acid (NeuAc-alpha 2-8)n, with n more 
than 10. In mammalian cells, most PSA is associated with neural cell adhesion molecule 
(NCAM). Expression of PSA-NCAM is abundant in embryonic nervous system. Using a 
monoclonal antibody specific to PSA-NCAM, we identified the expression of PSA not 
only in embryonic neurons (Figure 3-10), but also in neonatal microglia (Figure 3-11). To 
investigate whether Siglec-11 functions through PSA, EndoN was applied to remove PSA 
from NCAM in the cultures. The density of neurite and neuronal cell bodies was 
measured after co-culturing neurons and microglia transduced with Siglec-11 or control 
vector. It showed that when PSA was present in the neurons, co-cultures with Siglec-11 
expressing microglia had relatively higher neurite density and neuronal cell body density 
compared to the control co-cultures where microglia expressed control vector (Figure 
3-12). Particularly, the relative neurite density of co-cultures with Siglec-11 expressing 
microliga compared to those of control co-cultures was 1.6±0.2 times (mean±SEM) and 
1.8±0.2 times (mean±SEM) respectively when microglial PSA was or was not present. 
And the relative neuronal cell body density of co-cultures with Siglec-11 expressing 
microglia compared to those of control cultures was 2.1±0.4 times (mean±SEM) and 
2.1±0.3 times (mean±SEM) respectively when microglial PSA was or was not present. 
However, when PSA was removed from the neurons, the difference in the density of 
neurons was not observed anymore. Particularly, the relative neurite density of co-cultures 
with Siglec-11 expressing microliga compared to those of control cultures was 1.1±0.2 
times (mean±SEM) and 1.1±0.3 times (mean±SEM) respectively when microglial PSA 
was or was not present. And the relative neuronal cell body density compared to those of 
control cultures was 1.3±0.3 times (mean±SEM) and 1.0±0.2 times (mean±SEM) when 
microglial PSA was or was not present. This indicated that PSA expressed on the neurons 
but not on microlia might contribute to the neuronal protective function of Siglec-11. 
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Figure 3-10. Immunostaining of PSA-NCAM on cultured primary neurons. The 
mouse monoclonal anti-PSA-NCAM antibody and FITC conjugated secondary antibody 
were used to stain PSA-NCAM on embryonic neurons. Neurons were doubled stained 
with anti-β-tubulin III antibody and Cy3 conjugated secondary antibody. One the right 
panel, EndoN was applied the culture for 5 hours, which removed the PSA-NCAM from 
the neurons. Scale bar: 50 µm. 
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Figure 3-11. Immunostaining of PSA-NCAM on cultured primary microglia. The 
mouse monoclonal anti-PSA-NCAM antibody and Cy3 conjugated secondary antibody 
were used to stain the PSA-NCAM expression on primary microglia. Microglia were 
doubled stained with anti-Iba1 antibody and FITC conjugated secondary antibody. One 
the right panel, EndoN was applied the culture for 5 hours, which removed the 
PSA-NCAM from the microglia. Scale bar: 50 µm. 
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Figure 3-12. Co-culture of primary microglia with neurons. Microglia were 
lentivirally transduced with Siglec-11 or the control vector. PSA was removed from 
neurons and/or microglia by EndoN treatment for 5 hours at 37 0C. Cells were co-cultured 
for 48 hours. The fluorescence intensity of neurites stained with β-tubulin III was 
measured and statistically analyzed. Data are shown as mean +/- SEM, N=5, *: P<0.05. 
 
 
3.5 Generation of Siglec-11 expressing transgenic mice  
3.5.1 ES cell-embryo aggregation 
3.5.1.1 Establishment of ES cell lines for transgenic mice  
The MPI ES cell line and Bruce4 ES cell line were transduced with lentiviral particles 
carrying Iba1-Siglec-11. 48 hours post-transduction cells were selected in G418 for 10 
days. Colonies that survived were picked manually, and insertion of the vector was 
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verified by PCR amplification of the neomycin marker. Three lines of MPI ES cells 
(MPI-Siglec-11 ES cells) and 15 lines of Bruce4 ES cells (Bruce4-Siglec-11 ES cells) 
positively transduced with the transgene were established (Table 3-2). 
Table 3-2. Establishment of Siglec-11-ES cell lines 
ES cell line vector Number of established lines 
MPI Iba1-Siglec-11 3 
Bruce4 Iba1-Siglec-11 15 
 
3.5.1.2 Generation of chimeric mice  
Aggregation experiment was first carried out with the MPI ES cells. ES cells were 
aggregated to 8-cell-stage CD1 embryos. The non-modified ES cells were used as a 
control. From the control experiment, 2 chimeras with about 40-50% chimerism 
according to the hair color were generated. And one of these 2 mice showed germline 
transmission. Aggregation of MPI-Siglec-11 ES cells resulted in in total 8 chimeras with 
chimerism differing from about 20% to 80%, but none of these chimeras gave germline 
transmission. From the Bruce4-Siglec-11 ES cells, in total 17 chimeras were generated 
ranging from low chimerism (about 5%) to high chimerism (90%) (Figure 3-13). 
Unfortunately, also no germline transmisstion were established from these animals (Table 
3-3).  
Table 3-3 ES cell-embryo aggregation results 
ES cell line Vector Number of 
chimeras 
Percentage of 
Chimerism 
Germline 
transmitter 
MPI no 2 40-50% Yes 
MPI-Siglec-11 Iba1-Siglec-11 8 20-80% No 
Bruce4-Siglec-11 Iba1-Siglec-11 17 5-90% No 
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Figure 3-13. Representive photos of Siglec-11 chimeric mice generated from ES 
cell-embryo aggregation experiment with chimerism ranging from 5% to 90% according 
to the color of the hair. 
 
3.5.2 Transgenic mouse strains generated by pronuclear injection 
PLL-Iba1-Siglec-11 plasmid was digested with restriction enzymes BsiEI and Not1 to 
separate the Iba1 promoter, the cDNA of Siglec-11 together with the WPRE sequence 
from the plasmid backbone. The WPRE was kept to replace the function of poly A signal. 
The purified DNA fragment was injected into B6D2 F1 (F1 generation of DBA and 
C57/Bl6) mice zygotes. In total 21 founders were established according to genotyping by 
PCR (Table 3-4).  
 
Table 3-4 Generation of transgenic mice expressing Siglec-11 by pronuclear 
injection 
Zygote background Gene construct Founder Germline 
transmission 
Male Female B6D2 F1 (F1 generation of DBA + 
C57 Bl6 ) 
Iba1-Siglec-11-WPRE 
11 10 
Yes 
 
Ten of the founders were bred to C57/Bl6 mice. Germline transmission of Siglec-11 in the 
new generation was comfirmed by genotyping. The expression of Siglec-11 mRNA was 
confirmed by RT-PCR of the brain tissue. Furthermore, Western blot analysis verified 
that Siglec-11 was expressed in the brain tissue of transgenic mice (Figure 3-14). 
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Figure 3-14. Analysis of 3 representative strains of the F1 generation of the Siglec-11 
expressing transgenic mice. A. Genotyping of Siglec-11 from the mouse tails. B. 
RT-PCR analysis of the mRNA expression of Siglec-11 in the brain tissue. C. Western blot 
analysis of Siglec-11 in the brain tissue. 
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4 DISCUSSION 
4.1 Detection of a splice variant of Siglec-11 in the human brain 
In 2002, Siglec-11 was first described by Angata and coworkers (Angata, Kerr et al. 2002). 
In the search for novel Siglec candidates in human genomic DNA sequences, they 
identified a Siglec-like putative gene which was proven to be actively transcribed. They 
isolated the full-length coding region of the cDNA of this gene, which was denoted as 
Siglec-11, by PCR from a human fetal liver cDNA library and obtained the sequences of 
untranslated regions by 3’- and 5’- rapid amplification of cDNA ends (RACE). The 
structure of Siglec-11 was then digged out as having five extracellular Ig-like domains 
(one V-set Ig-like domain followed by 4 C-set Ig-like domains), a single-pass 
transmembrane domain, and a cytosolic tail. It contains almost all of the defined features 
of Siglecs including conserved amino acids (an Arg residue and an aromatic amino acid 
near the N terminus), and three conserved cysteine residues in the first and second Ig-like 
domans. By RT-PCR analysis of human multiple tissues cDNA panel using Siglec-11 
specific primers, they showed that the expected 400-bp band was prominent in cDNA 
from brain, placenta, lung, liver and pancreas, but undetectable in heart, skeletal muscle, 
and kidney. When using a monoclonal antibody 4C4 against Siglec-11 developed by 
themselves to analyze the protein expression in human tissues, they identified low but 
distinct expression of Siglec-11 in Kupffer cells in liver, intestinal lamina propria 
macrophages, brain microglia, and perifollicular cells in spleen, as well as in cells from 
tonsil and appendix, in a pattern similar but not completely overlapped to that of CD68. 
Based on their findings, we set out to study the function of Siglec-11 on brain microglia. 
We designed Siglec-11 specific primers from different exons from the coding region to 
verify the transcription of Siglec-11 in human brain tissue. However, the transcript we 
obtained from human brain tissue was different from what was reported by Angata and 
coworkers. A 288-bp long exon coding the 5th extracellular Ig-domain (the last C-set 
Ig-like domain next to the transmembrane domain) was missing. This was consistent in all 
of the three samples from different patients we analyzed. Interestingly, the cDNA 
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sequence of Siglec-11 which was derived from human placenta that we obtained from the 
German genetic material source center was identical to our finding. When we compared 
the protein size of the human brain Siglec-11 with the Siglec-11 overexpressed in 293 
using the short version of cDNA we obtained, there was no difference between them as 
determined by Western blot analysis. This comfirmed that the splice variant of Siglec-11 
(variant 2) we identified was expressed in all the human brain samples we were able to 
examine. After checking literature, indeed, the shorter version of Siglec-11 cDNA was 
reported somewhere else previously (Clark, Gurney et al. 2003). The reason why Angata 
and coworkers did not detect this variant was due to their design of the primers for 
RT-PCR. Actually, their primers were derived from the sequence coding the intracellular 
domain and the 3’- untranslated region of Siglec-11 cDNA, while we used primers 
derived from various exons including not only the extracellular domains but also the 
intracellular domain, which enabled us to detect the variation in the transcript of 
Siglec-11.  
However, it is also possible that the transcription of Siglec-11 differs in different tissue. 
The used brain tissue and the obtained placenta cDNA might have a shorter transcript, but 
other tissues which we did not analyze further might have a longer transcript of Siglec-11.  
From a structural point of view, the 5th Ig-like domain missing in the detected splice 
variant 2 of Siglec-11 does not seem to be a key factor affecting the function of Siglec-11. 
The so far known key elements of the Siglecs are mainly the N-terminal first V-set Ig-like 
domain, which recognizes and binds sialic acid, the second C-set Ig-like domain which 
might be required for effective recognizing of sialic acid by the V-set domain, and the 
intracellular tail which contains the ITIMs that might be involved in the signal 
transduction. The V-set like Ig-like domains are generally thought to only have the 
function of pointing the V-set domain away from the cell surface. Thus, it was reasonable 
for us to use the cDNA of the shorter variant of Siglec-11 in our further study. 
 
4.2 Siglec-11, an inhibitory immune receptor? 
Siglecs are emerging as important regulators of the immune system. One prominent 
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feature of the CD33 related family members including Siglec-11 is the two conserved 
ITIM-like motifs in the cytoplasmic regions. Numerous studies have showed that the 
ITIM containing Siglecs could function as inhibitory receptors that modulate leukocyte 
behaviour, including inhibition of cellular proliferation, induction of apoptosis, inhibition 
of cellular activation, induction of pro-inflammatory cytokine serection, and suppression 
of interferon-α production (Crocker, Paulson et al. 2007). 
 
4.2.1 Regulatory function of Siglec-11 on microglia 
Microglia have been implicated as active contributors to neuron damage in 
neurodegenerative diseases, in which the overactivation and dysregulation of microglia 
might result in disastrous and progressive neurotoxic consequences. 
Our study of Siglec-11 was focused on microglia, the brain macrophage. It was reported 
that in peripheral blood cells Siglec-11 was not detectable (Angata, Kerr et al. 2002) or 
only at a very low expression level (Nguyen, Hurtado-Ziola et al. 2006) by FACS. We 
check the expression of Siglec-11 in a human monocytic cell line. Indeed, no Siglec-11 
was detected. However, when we differentiate this cell line into macrophage, Siglec-11 
transcript was detected by RT-PCR. It is known that under some disease conditions, bone 
marrow derived monocytes could be recruited to the brain and differentiated into 
microglia. The induction of Siglec-11 in macrophages differentiated from monocytes 
implies a specific function of Siglec-11 in microglia/macrophage. 
LPS is the endotoxin derived form Gram-negative bacterial and is commonly used to 
mimic the infection condition. It is reported that LPS induces microglial activation in vivo 
and in vitro. In our study, under the stimulation of LPS, primary microglia transduced 
with Siglec-11 showed reduced expression of pro-inflammatory cytokines, namely IL-1β 
and NOS2, when a flag antibody was used to crosslink the Siglec-11, indicating an 
inhibitory effect of Siglec-11.  
The ability of phagocytosing the corpses of apoptotic cell is one of the key features of 
microglia. It was reported that glial phagocytic activity is mediated by ITAM signaling 
transducted by Src and Syk family kinase signaling (Ziegenfuss, Biswas et al. 2008). 
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There was also evidence that phagocytosis of apoptotic bodies by macrophages was 
inhibited with sialooligosaccharide ligands of siglec-5 and monoclonal antibodies (mAbs) 
to siglec-5 (Rapoport, Sapotko et al. 2005). In our study, the Aβ phagocytosis ability was 
impaired in Siglec-11-expressing primary microglia. Since the cytosolic tail of Siglec-11 
was very closely related to that of Siglec-5, which contains two ITIM motifs, it is possible 
that activation of these Siglecs triggered ITIM-mediated signalling which counteracted the 
ITAM signaling and lead to the inhibition of the phagocytosis.  
Activated microglia are known to be toxic to neurons by releasing a wide range of factors 
including glutamate, TNF-α, nitric oxide (NO) and IL-1β, which can actively trigger 
apoptosis in neuronal cell cultures (Bessis, Bechade et al. 2007). Here, we showed that 
Siglec-11 expressing microglial cells seem to have a less toxic impact to the integrity of 
neurons. This is consistent to our findings that Siglec-11 could inhibit the secretion of 
some of these factors such as IL-1β, and NOS2. 
 
4.2.2 ITIM mediated signaling in Siglecs 
  The importance of balancing positive and negative signals within the immune system is 
an emerging topic of discussion. When cellular activation is triggered by receptors with 
ITAMs, counteracting inhibitory signals are delivered through receptors bearing ITIMs. 
Following phosphorylation by Src-family kinases, ITIMs recruit phosphatases, either Src 
homology 2 domain-containing inositol polyphosphate 5’ phosphatase (SHIP), or more 
commonly SHP-1 and SHP-2. These phosphatases inhibit signaling pathways by distinct 
mechanisms, resulting in raised activation thresholds. The presence of two conserved 
ITIM-like motifs in the cytoplasmic regions of CD33-related Siglecs and the differential 
expression of these proteins on leukocytes suggests a role in regulating cellular activation. 
Functional evidence that Siglecs can mediate inhibitory signals has been obtained using 
mAbs to co-crosslink CD33 or mSiglec-E with an activating human receptor, FcγR1. This 
resulted in reduced Ca2+ influx compared with crosslinking FcγRI alone. Similarly, 
Siglec-7 was identified as an inhibitory NK-cell receptor in a redirected killing assay in 
which anti-Siglec-7 mAb was used to cluster Siglec-7 at the interface between NK cell 
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and target cell. In other functional studies, the addition of intact anti-CD33 or 
anti-Siglec-7 mAbs to hematopoietic cell cultures led to reduced cell growth and 
prevented the development of DCs (Crocker and Varki 2001). 
Siglec-11 has been shown to be able to recruit SHP-1 and SHP-2. When mouse 
macrophage-like cells RAW 264.7 stably transfected with Siglec-11 were treated with 
pervanadate, a potent inhibitor of tyrosine phosphatases, tyrosine phosphorylation was 
clearly evident, and this was accompanied by co-immunoprecipitation of both SHP-1 and 
SHP-2. And low levels of SHP-2 could even be seen in immunoprecipitates from 
non-pervanadate-treated cells, under conditions where phosphorylation of Siglec-11 was 
undetectable (Angata, Kerr et al. 2002). Our findings that human Siglec-11 expressed in 
microglia inhibited phagocytosis, reduced pro-inflammatory cytokine transcription and 
prevented neuronal damage enabled us to assign Siglec-11 as an inhibitory receptor in the 
immune system, in which ITIM signal transduction might be an important player. 
However, ingenious experiments need to be carried out to further comfirm the 
contribution of ITIM signaling. 
 
4.3 PSA, an endogenous ligand of Siglec-11? 
Siglec-11 has previously been shown to bind weakly but specifically to α-2–8-linked 
sialic acids (Neu5Ac-alpha 2-8), but the ligand molecule modified by 2-8-linked sialic 
acids and recognized by Siglec-11 has not been identified (Angata, 2002). PSA, which is 
present prominently in the nervous system, emerges as a possible ligand candidate for 
Siglec-11.  
PSA is the long linear homopolymers of α-2,8-linked Nacetylneuraminic acid 
( Neu5Ac-alpha 2-8). In mammalian cells, most PSA is associated with NCAM (Cremer, 
Lange et al. 1994). Expression of PSA is abundant in embryonic nervous system and is 
drastically reduced in the adult. PSA modification of NCAM during neuronal 
development has been shown to play a significant role in cell migration, axonal guidance, 
synapse formation, and functional plasticity by preventing the formation of stable cell 
contacts mediated by NCAM and other cell surface molecules (Bonfanti 2006). Although 
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overall PSA levels are greatly reduced in the adult brain, high levels of PSA persist in 
distinct regions that retain neurogenic capacity, such as the SVZ (Rousselot, Lois et al. 
1995) and the granule cell layer of the hippocampus (Seki and Arai 1991), or that exhibit 
physiological plasticity, such as regions of the hypothalamus, the entorhinal–hippocampal 
complex, the thalamus, the habenular nuclei, the mesencephalic central grey, the lateral 
geniculate nucleus and dorsal spinal laminae (Seki and Arai 1993; Bonfanti 2006). 
Perturbation of PSA levels has been shown to influence a wide range of CNS functions 
and PSA is revealed to be associated with cellular elements that are known to be directly 
involved in behavioural plasticity. Indeed, altered PSA levels are associated with various 
neuropathological conditions (Rousselot, Lois et al. 1995), including chronic stress (Pham, 
Nacher et al. 2003), Alzheimer’s disease (Mikkonen, Soininen et al. 1999), schizophrenia 
(Barbeau, Liang et al. 1995) and temporal lobe epilepsy (Mikkonen, Soininen et al. 1998).  
When studying possible ligands of Siglecs, one should always be cautious that these 
molecules might work both “in cis” and “in trans”. Although little PSA has been found in 
adult non-neural tissues, the immune system is the exception. For example, PSA is 
reported to be associated with dendritic cells, where expressed neuropilin-2 is 
polysialylated and influences the activation of T cells (Curreli, Arany et al. 2007). PSA is 
also found on the surface of natural killer cells (Moebius, Widera et al. 2007). Using a 
monoclonal antibody specific to PSA-NCAM, we also identified the expression of 
Siglec-11 in neonatal microglia. 
With the help of EndoN, which specifically removes PSA from NCAM, we were able to 
show that Siglec-11 appeared to have protective effect on neurons, which was associated 
with the presence of PSA on the neurons, but not on microglia. Thus, in our system, 
Sigelc-11 and PSA interact in a trans way, but not in cis.  
The common sialic acids of mammalian cells are Neu5Ac and Neu5Gc. Humans lack 
Neu5Gc owing to a mutation in the CMAH (cytidine monophosphate-N-acetylneuraminic 
acid hydroxylase) gene, which encodes the enzyme required for the conversion of 
Neu5Ac to Neu5Gc (Sonnenburg, Altheide et al. 2004). The loss of Neu5Gc in human has 
been proved to may alter biological processes of the siglecs, including siglec-1, and 
possibly, siglec-4a or -5 (Brinkman-Van der Linden, Sjoberg et al. 2000). Siglec-11 is a 
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receptor evolutionary appeared very late. In this regard, one can also postulate that 
Siglec-11 might adapt to the abundant Neu5Ac in the human CNS. Interestingly, PSA 
does not exist in invertebrate (Rutishauser 2008), which share many fundamental aspects 
of vertebrate neuronal function and circuitry. Given the correlation of PSA with physical 
and structural plasticity, it seems likely that the evolution of a less hardwired and more 
adaptive CNS has taken the advantages of PSA, thereby improving the ability to respond 
to changing environments. 
 
4.4 Transgenic mice expressing Siglec-11, a tool to study Siglec-11 
 In the effort to generate transgenic mice that express Siglec-11 specifically in brain 
microglia and tissue macrophages, we first tried the ES cell-mediated technology. 
However, the chimeras generated from the aggregation of modified ES cells and mouse 
embryos did not show gremline transmission ability. And the chimeras themselves were 
not ideal to study. So we applied the pronuclear injection technology later. Quite a few of 
founders were successfully generated. And by breeding of the founders to C57/BL6 mice, 
we have established more than five strains of transgenic mouse lines expressing Siglec-11 
in the brain which are valuble tools to study the function of Siglec-11. 
 
4.4.1 A source of Siglec-11 expressing cells for in vitro study 
The research on the function of microglial Siglec-11 was aggravated due to the difficulty 
of getting human microglial cells. Although mouse lacks the ortholog of Siglec-11, mouse 
microglia still would be a good system to study the signaling via Siglec-11 and the 
resulting effects since the intracellular signaling pathways are almost identical between 
mice and humans. Primary microglia expressing Siglec-11 without additional genetic 
modification steps such as viral transduction would save time and energy from the tedious 
but also critical preparation of the virus and the subsequent transduction. Furthermore, the 
difference of the cells used from experiments to experiments will be minimized. Data 
obtained from the in vitro study on these cells would provide insightful indication to the 
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features of Siglec-11. 
 
4.4.2 Facilitating the study of Siglec-11 in vivo  
As a human specific gene, Siglec-11 is found only in human and its unique expression 
pattern adds difficulty to the employment of human cells for analyzing its natural 
functions. However, the Siglec-11-expressing transgenic mice will make the functional 
study of Siglec-11 in vivo feasible. Particularly, the transgenic mice expressing Siglec-11 
in microglia facilitate the study of neuronal immunological diseases such as MS, AD, 
since mouse models are already available. For example, experimental autoimmune 
encephalomyelitis (EAE) can be induced in the Siglec-11 transgenic mice to see whether 
Siglec-11 has any impact on the disease process. Data obtained then will elucidate the 
functions of Siglec-11 in brain micrglia and its possible impact on the development or 
therapy of inflammatory and degenerative CNS diseases.  
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5 SUMMARY 
Siglec-11 is a recently identified human-specific CD33-related Siglec expressed on 
microglia. The full-length cDNA of Siglec-11 encodes 5 extracellular Ig-like domains, a 
single pass transmembrane domain, and a cytosolic tail, which contains ITIMs. In human, 
histopathology demonstrated the expression of Siglec-11 on tissue macrophages in 
various tissues, including microglia in brain. We studied Siglec-11 in microglia. A 
Siglec-11 splice variant, but no full length Siglec-11 was identified in human brain tissue 
samples. Functional analysis was performed in cultured mouse microglial cells lentivirally 
transduced with this splice variant of human Siglec-11. Under stimulation with LPS, gene 
transcription of IL-1β and NOS2 of microglia was reduced after cross-linking of 
Siglec-11. The Aβ phagocytosis ability was impaired in Siglec-11 expressing microglia. 
PSA-NCAM as a putative ligand of Siglec-11 was detected on microglia and neurons. 
Co-culture of microglia expressing Siglec-11 and neurons demonstrated neuroprotective 
function of Siglec-11. Neurite density and neuronal cell body density were higher in 
co-cultures with Siglec-11 expressing microglia than those of control co-cultures. 
Neuroprotective effect was dependent on sialic acid residues on neurons, but independent 
on polysialylated residues of microglia. Transgenic mice were generated expressing 
Siglce-11 under the microglial Iba1-promoter. Chimeric mice were obtained from 
aggregation of genetically modified ES cells and embryos, but no germline transmission 
was achieved. Germline transmission was obtained from pronuclear injection of Siglec-11 
DNA. Several strains of transgenic mice expressing Siglec-11 in the brain have been 
sucessfully established. Thus, data show that Siglec-11 is an inhibitory receptor of 
microglia that might help to create an immunosuppressive milieu in the CNS and alleviate 
microglial neurotoxicity. Humanized transgenic mice expressing Siglec-11 we have 
generated serve as a good model to provide valuble information on the natural features of 
Siglec-11. 
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